

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

Impact of donor with evidence of bacterial infections on deceased donor liver transplantation-A retrospective observational cohort study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-023908
Article Type:	Research
Date Submitted by the Author:	02-May-2018
Complete List of Authors:	Chan, Kun-Ming; Chang Gung Memorial Hospital Linkou Branch, General Surgery Cheng, Chih-Hsien; Chang Gung Memorial Hospital Linkou Branch, General Surgery Wu, Tsung-Han; Chang Gung Memorial Hospital Linkou Branch, General Surgery Lee, Chen-Fang; Chang Gung Memorial Hospital Linkou Branch, General Surgery Wu, Ting-Jung; Chang Gung Memorial Hospital Linkou Branch, General Surgery Chou, Hong-Shiue; Chang Gung Memorial Hospital Linkou Branch, General Surgery Lee, Wei-Chen; Chang Gung Memorial Hospital Linkou Branch, General Surgery
Keywords:	Transplant medicine < INTERNAL MEDICINE, Transplant surgery < SURGERY, TRANSPLANT SURGERY

SCHOLARONE™
Manuscripts

1
2
3
4 **Title: Impact of donor with evidence of bacterial infections on**
5
6 **deceased donor liver transplantation-A retrospective observational**
7
8 **cohort study**
9
10

11
12
13
14 **Authors:** Kun-Ming Chan, M.D.^{1,2}, Chih-Hsien Cheng, M.D.¹, Tsung-Han Wu,
15 M.D.¹, Chen-Fang Lee, M.D.¹, Ting-Jung Wu, M.D.¹, Hong-Shiue Chou, M.D.¹,
16 Wei-Chen Lee, M.D.¹
17

18
19
20
21 **Institutions:**

22 ¹Department of General Surgery & Department of Organs Transplantation Institute,
23 Chang Gung Memorial Hospital at Linkou, Chang Gung University College of
24 Medicine, Taoyuan, Taiwan.
25

26
27
28
29 ²**Correspondence information: Kun-Ming Chan, MD**

30 Department of General Surgery & Department of Organs Transplantation Institute,
31 Chang Gung Memorial Hospital at Linkou,
32 Chang Gung University College of Medicine, Taoyuan, Taiwan.
33

34 5 Fu-Hsing Street, Kwei-Shan District, Taoyuan City 33305, Taiwan

35 **E-mail:** chankunming@adm.cgmh.org.tw
36
37
38
39
40

41 **Running head:** donor bacterial infection on DDLT
42
43
44
45
46
47

48 **Words count:** 2146 words; 2 tables, 3 figures
49
50
51
52
53
54
55
56
57

Abstract

Objective: The shortage of available donor organs is an unsolvable concern leading to an expansion in the donor criteria for organ transplantation. Here, we describe our experience and assess the outcomes in recipients who obtained a graft from a donor with bacterial infections in deceased donor liver transplantation (DDLT).

Methods: All DDLTs between January 1991 and February 2017 were retrospectively reviewed. Patients were categorized into two groups based on recipients who obtained a graft from a donor with (Group I) or without (Group II) evidence of bacterial infections. Outcomes and bacterial infections were compared between the two groups of recipients.

Results: Overall, a total of 285 DDLTs were performed from 248 donors consisting of 48 split liver grafts and 208 whole liver grafts. Of those, 98 recipients (Group I, 34.3%) were transplanted with a graft from 78 donors with positive bacterial cultures. Donor sputum cultures had the highest rate of positive bacterial growth, accounting for 26.6% of donors. Overall survival was not significantly different between the two groups ($p=0.9746$). The overall survival rates at one and three years were 73.5% and 69.2% in the Group I recipients *versus* 68.8% and 62.4% in the Group II recipients. Importantly, no hospital mortality was related to donor-derived bacterial infections.

1
2
3
4 **Conclusion:** Transmission of bacteria from the donor to the recipient is infrequent in
5
6 DDLT. Therefore, potential donors with positive bacterial infections should not be
7
8 excluded for organ transplantation in order to increase organ availability and
9
10 ameliorate the organ shortage.
11
12
13

14
15
16
17
18
19 **Keywords:** deceased donor; bacterial infection; transmission; liver transplantation;
20
21
22 outcomes
23
24
25
26
27
28
29

30 **Strengths and limitations of this study**

- 31
32
33
34 1. The shortage of deceased organ donors is stringent in Oriental Countries as
35
36 compared with Western Countries, and thus every donor should be carefully judged
37
38 for organ transplantation in order to achieve greatest effectiveness.
39
40
41
42
43 2. This study enrolled 285 deceased donor liver transplantation in the setting of scarce
44
45 organ donation, and analyzed the influence of donors with evidence of bacterial
46
47 infections on liver transplantation.
48
49
50
51
52 3. The results show that the incidence of donor-transmitted bacterial infections was
53
54
55 very low, suggesting that donors with a bacterial infection should not be excluded as
56
57
58
59
60

1
2
3 organ donors for liver transplantation.

4
5
6
7 4. The study is limited by its retrospective entity in a single transplantation center

8
9
10 with a small number of patients.
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Introduction

Organ transplantation is a promising alternative for the treatment of many end-stage diseases. However, the discrepancy between organ demand and donor availability is currently an unsolvable concern. Therefore, expanded donor criteria including older donors, circulatory death donors, or donors with mild diseases and so forth are increasingly used as donors for organ transplantation. Subsequently, there is a high possibility of the transmission of unwanted infectious diseases following organ donation. Infectious microbes including viruses, bacteria, parasites and fungi that are present in organ donors have the potential to be transmitted to the transplant recipient.(1-3)

Among these infectious microbes, any active bacterial infection in the donor may result in a lethal complication immediately after transplantation if bacteria are transmitted to the recipient during organ transplantation. Thus, the majority of transplantation surgeons are reluctant to transplant organs known to be infected by active bacteria. Specifically, the deceased donor shortage is very high particularly in Oriental countries. In this study, we gathered our experience in deceased donor liver transplantation (DDLT) and analyzed data regarding donors with bacterial infections to assess the influence of an infected donor on the outcome of the recipient. These

1
2
3
4 results provide additional information for the selection of deceased donors for liver
5
6 transplantation (LT).
7
8
9
10

11 12 13 14 **Methods**

15 16 17 18 ***Patients***

19
20
21 A total of 285 consecutive DDLTs were performed during the period between January
22
23 1991 and February 2017 at the Transplantation Institute. All medical records of
24
25 donors and recipients were retrospectively reviewed under the approval from the
26
27 Institutional Review Board of Chang Gung Memorial Hospital. Of all LT, liver grafts
28
29 were procured from 248 donors including 81 donors from the national organ sharing
30
31 program and 167 donations from the institute. No executed prisoner organs were used
32
33 in this study. Liver graft donations and transplantations are illustrated in Figure 1.
34
35
36 Overall, 40 donors underwent split liver donation, and whole liver grafts were
37
38 procured from the 208 donors. Among whole liver donors, 13 donors had reduced size
39
40 liver grafts from a partial liver resected *ex vivo* in order to be implanted in recipients
41
42 with a relatively small abdominal cavity. Written informed consent was obtained from
43
44
45
46
47
48
49
50
51
52
53 all patients included.
54
55
56
57
58
59
60

Donor survey

All potential donors were thoroughly checked by laboratory tests for hepatitis B and C virus, human immunodeficiency virus (HIV), cytomegalovirus (CMV), Epstein-Barr virus (EBV), toxoplasmosis and syphilis. Generally, chest radiography and ultrasonography of the heart, liver and kidney would be routinely performed prior to the donation of solid organs. With regard to the assessment of bacterial infection, serial samples including bronchial aspirates, urine and blood were usually obtained for culture. If the donor was eligible for organ donation, transplantation surgeons would proceed to organ procurement after the determination of brain death by specialists.

The decision to perform split liver grafts in two adult recipients was based on preoperative hepatic sonography and an intraoperative assessment of the liver graft. Transection of the hepatic parenchyma for split liver grafts was all performed *in situ* as previously described.⁽⁴⁾ Importantly, bile was routinely obtained through the common bile duct for bacterial culture before flushing the biliary tree during liver graft procurement from all donors.

Liver transplantation recipients

All graft implantations were performed using standard techniques without

1
2
3
4 venovenous bypass. Generally, prophylactic antibiotics were usually administered for
5
6 all recipients after transplantation unless the susceptibility profile required specific
7
8 antibiotics prior to transplantation. The selection of prophylactic antibiotics was based
9
10 on the illness of recipients, in which third-generation cephalosporins was given to
11
12 recipients with Model For End-Stage Liver Disease (MELD) scores less than 20; a
13
14 combination of vancomycin and imipenem/cilastatin was administered to recipients
15
16 with MELD scores above 20. The use of antifungal prophylaxis was optional for
17
18 recipients who had high risk of fungal infections such as longer hospitalization before
19
20 transplantation, longer operation time, massive blood loss and blood transfusion
21
22 during the operation. The immunosuppressive regimen for recipients after
23
24 transplantation mainly consisted of a combination of methylprednisolone, tacrolimus
25
26 and mycophenolate mofetil, adjusted based on the clinical assessment of the recipient.
27
28
29
30
31
32
33
34
35
36
37

38 ***Outcomes and statistical analysis***

39
40
41
42 Recipients were categorized into two groups: Group I consisted of recipients
43
44 transplanted with a graft procured from a donor with a positive bacterial culture, and
45
46
47
48 Group II included recipients who obtained a graft from a donor without evidence of
49
50
51 bacterial infection. Bacterial infection was intensively monitored using samples from
52
53
54 the blood, drainage tubes and catheters for all recipients after LT. Microorganisms
55
56
57
58
59
60

1
2
3
4 than grew in all cultures within 30 days after LT were recorded and assessed for
5
6 bacterial infection transmission from donor. The recipient's outcome measure was
7
8 overall survival (OS), which was calculated from the date of LT to the date of death or
9
10 the end of this study. Survival curves were constructed by the Kaplan-Meier method,
11
12 and further compared by the log rank test. All data were analyzed using the statistical
13
14 software SPSS version 20.0 (IBM Inc., Armonk, NY, USA) for Windows. A *p*-value
15
16 of < 0.05 was defined as statistically significant.
17
18
19
20
21
22
23

24 ***Patient and public involvement statement***

25
26
27
28 This study was a retrospective observational study. Patients were not involved in this
29
30 study.
31
32
33
34
35
36
37

38 **Results**

39 ***Donor features***

40
41
42
43 All donors underwent donation after brain death; the 248 donors consisted of 174
44
45 males and 74 females. The median age of the donors was 40 years old, and ranged
46
47 from 9 to 75 years old. The major causes of brain death were cerebrovascular
48
49 accidents in 137 donors (55.2%) and head injury in 48 donors (19.4%). The median
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 duration of stay in the intensive care unit before donation was 3 days (ranging from 1
5
6 to 95 days).
7
8
9

10 Overall, 78 donors (31.5%) had positive bacterial culture samples, in which 3 (1.2%)
11
12 of them were with triple site positives, 13 (5.2%) were double site positives, and 62
13
14 (25%) were only single site positive (Fig. 2). Most positive bacterial cultures were
15
16 from bronchial aspirates of sputum, which were noted in 66 donors that accounted for
17
18 26.6% of all donors and 84.6% of donors with positive bacterial infections.
19
20
21
22

23 Additionally, bacterial growth was detected in 13 donors (5.2%) from blood cultures,
24
25 16 donors (6.5%) from urine cultures, and 7 donors (2.8%) from bile cultures.
26
27
28
29

30 ***Microorganisms in donor cultures***

31
32 All positive bacterial cultures derived from donors are described in Table 1. A total of
33
34 21 bacterial species were identified, including 9 Gram-positive, 11 Gram-negative,
35
36 and 1 Gram-variable. Among these, the three most common bacteria were *Klebsiella*
37
38 *pneumoniae* (n=34), *Staphylococcus aureus* (n=32), and *Escherichia coli* (n=13).
39
40
41
42

43 *Coagulase-negative Staphylococcus* was the first ranked bacterium found in the blood
44
45 cultures of 7 donors, and *Escherichia coli* was the most common bacterium found in
46
47 the urine cultures of 8 donors. *Klebsiella pneumoniae* was isolated from 32 donor
48
49 sputum cultures and 2 donor bile cultures. Additionally, *Pseudomonas aeruginosa*, a
50
51
52
53
54
55
56

relative common nosocomial species, was cultivated from 10 donor sputum cultures.

Recipient outcomes

Among the 285 DDLTs, 98 recipients (Group I) obtained grafts from 78 donors with positive bacterial cultures, while the remaining 187 recipients (Group II) were

transplanted with grafts from 170 donors who had no evidence of bacterial infection.

The clinical characteristics of recipients are summarized and compared in Table 2.

The majority of clinical features were similar between the two groups. However, the mean recipient age in Group I was significantly greater than that of Group II

recipients ($p = 0.002$), and a significantly higher ratio of Group II recipients received

whole liver grafts for transplantation ($p = 0.0002$). Importantly, the rates of bacterial

growth from blood cultures and hospital mortality within 30 days after LT were not

significantly different between the two groups.

In Group I, only one recipient (1.02%) had *Acinetobacter baumannii* detected in a

blood culture after LT, which was the same bacterium cultured from the donor's

sputum prior to organ donation. The recipient was indicated for LT due to hepatitis B

virus-related end stage liver cirrhosis, and obtained a right liver graft from a split liver

donation. However, no evidence of *Acinetobacter baumannii* growth was noted in the

blood culture in the other recipient who received a left liver graft from the same donor.

1
2
3
4 The groups of patients who obtained grafts from donor with and without bacterial
5
6 infection were compared and similar outcomes were found between the two groups
7
8
9 (Fig. 3, $p = 0.9746$). The analysis of the survival curves showed that the overall
10
11 survival rates at one and three years were 73.5% and 69.2% in Group I recipients,
12
13 while the corresponding values were 68.8% and 62.4% in Group II recipients.
14
15
16
17
18
19
20
21

22 Discussion

23
24
25
26 Although LT is currently considered the definitive treatment for individuals with
27
28 end-stage liver disease, unexpected transmission of infections from the donor to the
29
30 recipient remains a major concern. Although rare, complication related to
31
32 donor-derived infectious disease are associated with significant morbidity and
33
34 mortality. (3, 5-7) Among the types of donor-derived infections, bacterial transmission
35
36 from the donor could result in bacteremia immediately after transplantation and lead
37
38 to lethal complications. However, deceased donors are extremely rare in Oriental
39
40 countries, and the organ shortage for LT is exceptionally large as compared with
41
42 Western countries.(8, 9) Therefore, every donor should be carefully judged for organ
43
44 transplantation. This study analyzed donors in terms of bacterial infections in the
45
46 setting of scarce organ donation. The results show that the incidence of
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 donor-transmitted bacterial infections was very low, suggesting that donors with a
5
6 bacterial infection should not be excluded as organ donors for LT.
7
8
9

10 Generally, bacteria are the most common cause of infections in LT recipients.

11
12 However, opportunistic infections are generally uncommon in the first 1-4 weeks after
13
14 transplantation, depending on the recipient's net state of immunosuppression. Thus,
15
16 unexplained early infections in this period are generally associated with
17
18 surgery-related complications or donor-derived infections. This study examined all
19
20 recipient blood cultures for bacteria within 30 days after LT to match the donor's
21
22 bacterial infection. In line with previous reports, the incidence of possible bacterial
23
24 transmission from the donor was very low.(10, 11) Only one recipient's blood culture
25
26 had the same bacterium as the donor, and accounted for only 1.02% of all recipients in
27
28 the current study.
29
30
31
32
33
34
35
36
37
38

39 *Acinetobacter baumannii* is a typical Gram-negative bacterium that can be an
40
41 opportunistic pathogen affecting patients with compromised immune systems.(12, 13)
42
43
44

45 However, the recipient who obtained the left liver graft from the same donor had no
46
47 evidence of this bacterium in their blood cultures after LT. Therefore, the recipient's
48
49 pathogen could be a hospital-derived nosocomial infection instead of transmission
50
51 from donor. Meanwhile, liver grafts are usually flushed with organ preserving
52
53
54
55
56
57
58
59
60

1
2
3
4 solution during organ procurement, and re-perfused with more than 1500 ml/min of
5
6 the recipient's blood after graft implantation. As such, bacteria within the liver graft
7
8 are likely to be diluted by these process, and the chance of donor-derived bacterial
9
10 infection in the recipient is very low.
11
12
13
14

15
16 Our data are similar to previous reports showing that the highest positive rate of
17
18 bacterial culture of the donor was from sputum cultures.(11, 14) The most common
19
20 pathogens cultivated from bronchial aspirates of the donors in this study were
21
22 *Klebsiella pneumoniae* and *Staphylococcus aureus*. Both pathogens are members of
23
24 the normal flora of the body, and are frequently found in the respiratory tract and
25
26 skin.(15, 16) *Klebsiella* infections are mostly seen in people with a weakened immune
27
28 system or a nosocomial infection, and *Staphylococcus aureus* is not always
29
30 pathogenic. Additionally, *Escherichia coli* was the most common pathogen found in
31
32 the urine cultures of our donor, which might be related to either translocation from the
33
34 gastrointestinal tract or contamination with feces. Therefore, culture results from
35
36 donors that show these pathogens could be ignored so the donors are not excluded
37
38 from organ donation.
39
40
41
42
43
44
45
46
47
48
49

50
51 Importantly, each potential donor should be comprehensively screened for medical
52
53 conditions that may affect the recipient, which might include the presence of
54
55
56
57
58
59
60

1
2
3
4 transmissible disease, malignancies, or any other known condition that may be
5
6 transmitted by the donor organ. However, it is currently impossible to screen potential
7
8 donors for all potential pathogens during the narrow timeframe of the organ donation
9
10 process. Specifically, bacterial cultures of potential donors take time and may not
11
12 provide results prior to organ procurement for transplantation. Likewise, a donor may
13
14 have a bacterial infection that has been appropriately treated. Under such
15
16 circumstances, treatment of the recipient for the recognized infection immediately
17
18 after transplantation might be satisfactory.
19
20
21
22
23
24
25
26

27 **Conclusions**

28
29
30 Although the study is limited by its retrospective entity in a single transplantation
31
32 center with a small number of patients, several marked observation might be helpful
33
34 in clinical practice. Additionally, available organ donor numbers lag behind current
35
36 and future needs, and this organ shortage has thus forced clinicians to expand the
37
38 donor pool by using donors with the risk of transmitting infectious diseases. The
39
40 annual deceased organ donation rate has recently increased to 12.3 per million
41
42 population in Taiwan, but the number of DDLTs is still not satisfactory, with an
43
44 average of 100 cases per year.⁽¹⁷⁾ Many other counties may also encounter this
45
46 situation regarding deceased donor organ transplantation and LT. As a result, a
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 bacterial infection in the donor should not preclude the use of organs for
5
6 transplantation. Moreover, the possibility of bacterial transmission from the donor
7
8
9 seems to extremely low considering fluid dilution and the non-specific culture results.
10
11
12
13
14
15

16 **Author contributions:**

17 Study concept, design and drafting the manuscript: Kun-Ming Chan
18 Acquisition of data: Kun-Ming Chan, Tsung-Han Wu, Chih-Hsien Cheng, Chen-Fang
19 Lee, Ting-Jung Wu, Hong-Shiue Chou, Wei-Chen Lee
20
21 Critical revision of the manuscript for important intellectual content: Kun-Ming Chan,
22 Wei-Chen Lee
23
24
25

26 **Funding:** This research received no specific grant from any funding agency in the
27 public, commercial or not-for-profit sectors.
28
29

30 **Competing interests:** All authors have no conflict of interest.
31
32

33 **Patient consents:** Obtained.
34
35

36 **Ethics approval:** The Institutional Review Board of Chang Gung Memorial Hospital
37
38 (Approval No.: 98-3794B)
39
40
41
42

43 **Data sharing statement:** No additional data available.
44
45
46
47
48
49

50 **References**

- 51
52 1. Fishman JA. Infection in solid-organ transplant recipients. N. Engl. J. Med
53 2007;357:2601-2614.
54
55 2. Fishman JA. Infection in Organ Transplantation. Am J Transplant
56 2017;17:856-879.
57
58
59
60

3. Ison MG, Grossi P, Practice ASTIDCo. Donor-derived infections in solid organ transplantation. *Am J Transplant* 2013;13 Suppl 4:22-30.
4. Lee WC, Chan KM, Chou HS, Wu TJ, Lee CF, Soong RS, Wu TH, et al. Feasibility of split liver transplantation for 2 adults in the model of end-stage liver disease era. *Ann Surg* 2013;258:306-311.
5. Ison MG, Nalesnik MA. An update on donor-derived disease transmission in organ transplantation. *Am J Transplant* 2011;11:1123-1130.
6. Cerutti E, Stratta C, Romagnoli R, Serra R, Lepore M, Fop F, Mascia L, et al. Bacterial- and fungal-positive cultures in organ donors: clinical impact in liver transplantation. *Liver Transpl* 2006;12:1253-1259.
7. Lumbreras C, Sanz F, Gonzalez A, Perez G, Ramos MJ, Aguado JM, Lizasoain M, et al. Clinical significance of donor-unrecognized bacteremia in the outcome of solid-organ transplant recipients. *Clin Infect Dis* 2001;33:722-726.
8. Lo CM. Deceased donation in Asia: challenges and opportunities. *Liver Transpl* 2012;18 Suppl 2:S5-7.
9. Wang TH, Lee PC, Chiang YJ. Taiwan's organ donation and transplantation: Observation from national registry point of view. *J Formos Med Assoc* 2017;116:649-651.
10. Outerelo C, Gouveia R, Mateus A, Cruz P, Oliveira C, Ramos A. Infected donors in renal transplantation: expanding the donor pool. *Transplant Proc* 2013;45:1054-1056.
11. Yuan X, Chen C, Zhou J, Han M, Wang X, Wang C, He X. Organ Donation and Transplantation From Donors With Systemic Infection: A Single-Center Experience. *Transplant Proc* 2016;48:2454-2457.
12. Antunes LC, Visca P, Towner KJ. *Acinetobacter baumannii*: evolution of a global pathogen. *Pathog Dis* 2014;71:292-301.
13. Yeom J, Shin JH, Yang JY, Kim J, Hwang GS. (1)H NMR-based metabolite profiling of planktonic and biofilm cells in *Acinetobacter baumannii* 1656-2. *PLoS One* 2013;8:e57730.
14. Paredes D, Gamba MP, Cervera C, Linares L, Almela M, Rodriguez C, Ruiz A, et al. Characterization of the organ donor with bacteremia. *Transplant Proc* 2007;39:2083-2085.
15. Kluytmans J, van Belkum A, Verbrugh H. Nasal carriage of *Staphylococcus aureus*: epidemiology, underlying mechanisms, and associated risks. *Clin Microbiol Rev* 1997;10:505-520.
16. Podschun R, Ullmann U. *Klebsiella* spp. as nosocomial pathogens: epidemiology, taxonomy, typing methods, and pathogenicity factors. *Clin Microbiol Rev* 1998;11:589-603.

- 1
2
3 17. Wang TH, Chang YP, Chiang WL. Improving Donation Rates in Taiwan.
4 Transplantation 2016;100:2235-2237.
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Table 1. Microorganisms cultured from donors.

Micro-organisms	Bacterial cultures				Total
	Sputum	Urine	Blood	Bile	
Gram-positive bacteria					
<i>Staph.aureus</i>	31	-	1	-	32
<i>coagulase-negative staphylococcus</i>	-	-	7	1	8
<i>Enterococcus faecalis</i>	-	5	1	-	6
<i>staphylococcus</i>	1	-	2	-	3
<i>Streptococcus pneumoniae</i>	3	-	-	-	3
<i>Staph.epidermidis</i>	-	1	1	-	2
<i>Aerococcus</i>	-	-	-	1	1
<i>Enterococcus faecium</i>	-	-	-	1	1
<i>Propionibacterium acnes</i>	-	-	-	1	1
Gram-negative bacteria					
<i>Klebsiella pneumoniae</i>	32	-	-	2	34
<i>Escherichia coli</i>	4	8	-	1	13
<i>Pseudomonas aeruginosa</i>	10	2	-	-	12
<i>Haemophilus influenzae</i>	8	-	-	-	8
<i>Enterobacter cloacae</i>	4	3	-	-	7
<i>Acinetobacter baumannii</i>	5	-	1	-	6
<i>Stenotrophomonas maltophilia</i>	2	2	1	1	6
<i>Enterobacter aerogenes</i>	4	-	1	-	5
<i>Veillonella sp</i>	-	-	2	-	2
<i>Proteus mirabilis</i>	2	-	-	-	2
<i>Serratia marcescens</i>	2	-	-	-	2
other					
<i>Gardnerella vaginalis</i>	-	1	-	-	1

Number represent number of patients

Table 2. Recipient characteristics related to donor with or without positive bacterial culture

status.

Characteristics	Donor with positive bacterial cultures		<i>p</i> value
	Group I: Yes, <i>n</i> =98	Group II: No, <i>n</i> =187	
Age, median (range)	52 (33–65)	48 (1–67)	0.002
Sex (Male:Female)	77:21	132:55	0.160
Hepatitis status			0.403
Hepatitis B positive	51 (52.0%)	110 (58.8%)	
Hepatitis C positive	21 (21.4%)	27 (14.5%)	
Hepatitis B, C positive	3 (3.1%)	9 (4.8%)	
None	23 (23.5%)	41 (21.9%)	
Indication of LT			0.147
Alcoholic Liver cirrhosis	16 (16.3%)	10 (5.4%)	
Virus-related liver cirrhosis	40 (40.8%)	98 (52.4%)	
Hepatocellular carcinoma	32 (32.7%)	46 (24.6%)	
Others	10 (10.2%)	33 (17.6%)	
MELD score, median (range)	21 (7–40)	23 (7–40)	0.673
Type of grafts			0.0002
Whole liver graft	53 (54.1%)	142 (75.9%)	
Partial liver graft*	45 (45.9%)	45 (24.1%)	
Blood culture after LT (30days)			0.173
Positive bacterial growth	11 (11.2%)	12 (6.4%)	
Negative bacterial growth	87 (88.8%)	175 (93.6%)	
Hospital Mortality (30days)	11 (11.2%)	23 (12.3%)	0.849

LT, liver transplantation; MELD, Model for End-stage Liver Disease. *partial liver grafts included split liver and reduced size liver grafts.

1
2
3
4 **Figure legend**
5
6

7 **Figure 1.** Flow diagram of organ donors and liver transplantations assessed in this
8
9
10 study.
11
12

13
14
15
16
17 **Figure 2.** The rate of positive bacterial cultures in donors.
18
19
20

21
22 **Figure 3.** Comparison of cumulative overall survival for the patients showing no
23 significant difference between the two groups. Group I (···), Group II (—).
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Figure 1.




Figure 1

270x152mm (120 x 120 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 2.

254x138mm (120 x 120 DPI)




Figure 3.

254x176mm (120 x 120 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Reporting checklist for cohort study.

Based on the STROBE cohort guidelines.

Instructions to authors

Complete this checklist by entering the page numbers from your manuscript where readers will find each of the items listed below.

Your article may not currently address all the items on the checklist. Please modify your text to include the missing information. If you are certain that an item does not apply, please write "n/a" and provide a short explanation.

Upload your completed checklist as an extra file when you submit to a journal.

In your methods section, say that you used the STROBE cohort reporting guidelines, and cite them as:

von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: guidelines for reporting observational studies.

		Reporting Item	Page Number
Title	#1a	Indicate the study's design with a commonly used term in the title or the abstract	1
Abstract	#1b	Provide in the abstract an informative and balanced summary of what was done and what was found	2,3
Background / rationale	#2	Explain the scientific background and rationale for the investigation being reported	5
Objectives	#3	State specific objectives, including any prespecified hypotheses	5,6
Study design	#4	Present key elements of study design early in the paper	5,6
Setting	#5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	6,7
Eligibility criteria	#6a	Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up.	6,7

1		#6b	For matched studies, give matching criteria and number of	8,9
2			exposed and unexposed	
3				
4	Variables	#7	Clearly define all outcomes, exposures, predictors, potential	8,9
5			confounders, and effect modifiers. Give diagnostic criteria, if	
6			applicable	
7				
8				
9				
10	Data sources /	#8	For each variable of interest give sources of data and details of	8,9
11	measurement		methods of assessment (measurement). Describe	
12			comparability of assessment methods if there is more than one	
13			group. Give information separately for for exposed and	
14			unexposed groups if applicable.	
15				
16				
17				
18	Bias	#9	Describe any efforts to address potential sources of bias	7
19				
20	Study size	#10	Explain how the study size was arrived at	6
21				
22				
23	Quantitative	#11	Explain how quantitative variables were handled in the	8,9
24	variables		analyses. If applicable, describe which groupings were chosen,	
25			and why	
26				
27				
28	Statistical	#12a	Describe all statistical methods, including those used to control	8,9
29	methods		for confounding	
30				
31				
32		#12b	Describe any methods used to examine subgroups and	8,9
33			interactions	
34				
35				
36		#12c	Explain how missing data were addressed	See note
37				1
38				
39		#12d	If applicable, explain how loss to follow-up was addressed	See note
40				2
41				
42				
43		#12e	Describe any sensitivity analyses	See note
44				3
45				
46				
47	Participants	#13a	Report numbers of individuals at each stage of study—eg	9
48			numbers potentially eligible, examined for eligibility, confirmed	
49			eligible, included in the study, completing follow-up, and	
50			analysed. Give information separately for for exposed and	
51			unexposed groups if applicable.	
52				
53				
54				
55				
56		#13b	Give reasons for non-participation at each stage	n/a
57				
58		#13c	Consider use of a flow diagram	See note
59				
60				

1				
2				
3	Descriptive data	#14a	Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders. Give information separately for exposed and unexposed groups if applicable.	9-11
4				
5				
6				
7				
8				
9		#14b	Indicate number of participants with missing data for each variable of interest	See note 5
10				
11		#14c	Summarise follow-up time (eg, average and total amount)	11
12				
13	Outcome data	#15	Report numbers of outcome events or summary measures over time. Give information separately for exposed and unexposed groups if applicable.	11
14				
15				
16				
17				
18				
19				
20	Main results	#16a	Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	See note 6
21				
22				
23				
24				
25				
26				
27		#16b	Report category boundaries when continuous variables were categorized	n/a
28				
29				
30				
31		#16c	If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	n/a
32				
33				
34				
35	Other analyses	#17	Report other analyses done—e.g., analyses of subgroups and interactions, and sensitivity analyses	n/a
36				
37				
38				
39	Key results	#18	Summarise key results with reference to study objectives	12
40				
41	Limitations	#19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias.	15
42				
43				
44				
45				
46	Interpretation	#20	Give a cautious overall interpretation considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence.	15
47				
48				
49				
50				
51	Generalisability	#21	Discuss the generalisability (external validity) of the study results	15
52				
53				
54				
55	Funding	#22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which	16
56				
57				
58				
59				
60				

the present article is based

Author notes

1. n/a, no missing data
2. n/a, no loss follow-up patient
3. n/a, not applicable
4. 6, figure 1
5. n/a, no missing data
6. n/a, not applicable

The STROBE checklist is distributed under the terms of the Creative Commons Attribution License CC-BY. This checklist was completed on 30. April 2018 using <http://www.goodreports.org/>, a tool made by the [EQUATOR Network](#) in collaboration with [Penelope.ai](#)

BMJ Open

Impact of donor with evidence of bacterial infections on deceased donor liver transplantation-A retrospective observational cohort study in Taiwan

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-023908.R1
Article Type:	Research
Date Submitted by the Author:	08-Aug-2018
Complete List of Authors:	Chan, Kun-Ming; Chang Gung Memorial Hospital Linkou Branch, General Surgery Cheng, Chih-Hsien; Chang Gung Memorial Hospital Linkou Branch, General Surgery Wu, Tsung-Han; Chang Gung Memorial Hospital Linkou Branch, General Surgery Lee, Chen-Fang; Chang Gung Memorial Hospital Linkou Branch, General Surgery Wu, Ting-Jung; Chang Gung Memorial Hospital Linkou Branch, General Surgery Chou, Hong-Shiue; Chang Gung Memorial Hospital Linkou Branch, General Surgery Lee, Wei-Chen; Chang Gung Memorial Hospital Linkou Branch, General Surgery
Primary Subject Heading:	Surgery
Secondary Subject Heading:	Gastroenterology and hepatology, Infectious diseases, Medical management
Keywords:	Transplant medicine < INTERNAL MEDICINE, Transplant surgery < SURGERY, TRANSPLANT SURGERY

SCHOLARONE™
Manuscripts

1
2
3
4 **Title: Impact of donor with evidence of bacterial infections on**
5
6 **deceased donor liver transplantation-A retrospective observational**
7
8 **cohort study in Taiwan**
9
10

11
12
13
14 **Authors:** Kun-Ming Chan, M.D.^{1,2}, Chih-Hsien Cheng, M.D.¹, Tsung-Han Wu,
15 M.D.¹, Chen-Fang Lee, M.D.¹, Ting-Jung Wu, M.D.¹, Hong-Shiue Chou, M.D.¹,
16 Wei-Chen Lee, M.D.¹
17
18

19
20
21 **Institutions:**

22 ¹Department of General Surgery & Department of Organs Transplantation Institute,
23 Chang Gung Memorial Hospital at Linkou, Chang Gung University College of
24 Medicine, Taoyuan, Taiwan.
25
26

27
28
29 ²**Correspondence information: Kun-Ming Chan, MD**

30 Department of General Surgery & Department of Organs Transplantation Institute,
31 Chang Gung Memorial Hospital at Linkou,
32 Chang Gung University College of Medicine, Taoyuan, Taiwan.
33
34 5 Fu-Hsing Street, Kwei-Shan District, Taoyuan City 33305, Taiwan
35

36 **E-mail:** chankunming@adm.cgmh.org.tw
37
38

39
40
41 **Running head:** donor bacterial infection on DDLT
42
43
44
45
46
47

48 **Words count:** 2146 words; 2 tables, 3 figures
49
50
51
52
53
54
55
56
57

Abstract

Objective: The shortage of available donor organs is an unsolvable concern leading to an expansion in the donor criteria for organ transplantation. Here, we describe our experience and assess the outcomes in recipients who obtained a graft from a donor with bacterial infections in deceased donor liver transplantation (DDLT).

Methods: All DDLTs between January 1991 and February 2017 were retrospectively reviewed. Patients were categorized into two groups based on recipients who obtained a graft from a donor with (Group I) or without (Group II) evidence of bacterial infections. Outcomes and bacterial infections were compared between the two groups of recipients.

Results: Overall, a total of 285 DDLTs were performed from 248 donors consisting of 48 split liver grafts and 208 whole liver grafts. Of those, 98 recipients (Group I, 34.3%) were transplanted with a graft from 78 donors with positive bacterial cultures. Donor sputum cultures had the highest rate of positive bacterial growth, accounting for 26.6% of donors. Overall survival was not significantly different between the two groups ($p=0.9746$). The overall survival rates at one and three years were 73.5% and 69.2% in the Group I recipients *versus* 68.8% and 62.4% in the Group II recipients. Importantly, no hospital mortality was related to donor-derived bacterial infections.

Conclusion: Transmission of bacteria from the donor to the recipient is infrequent in DDLT. Therefore, potential donors with positive bacterial infections should not be excluded for organ transplantation in order to increase organ availability and ameliorate the organ shortage.

Keywords: deceased donor; bacterial infection; transmission; liver transplantation; outcomes

Strengths and limitations of this study

1. The shortage of deceased organ donors is stringent in Oriental Countries as compared with Western Countries, and thus every donor should be carefully judged for organ transplantation in order to achieve greatest effectiveness.
2. This study enrolled 285 deceased donor liver transplantation in the setting of scarce organ donation, and analyzed the influence of donors with evidence of bacterial infections on liver transplantation.
3. The results show that the incidence of donor-transmitted bacterial infections was very low, suggesting that donors with a bacterial infection should not be excluded as

1
2
3 organ donors for liver transplantation.
4

5
6
7 4. The study is limited by its retrospective entity in a single transplantation center
8

9
10 with a small number of patients.
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Introduction

Organ transplantation is a promising alternative for the treatment of many end-stage diseases. However, the discrepancy between organ demand and donor availability is currently an unsolvable concern. Therefore, expanded donor criteria including older donors, circulatory death donors, or donors with mild diseases and so forth are increasingly used as donors for organ transplantation. Subsequently, there is a high possibility of the transmission of unwanted infectious diseases following organ donation. Infectious microbes including viruses, bacteria, parasites and fungi that are present in organ donors have the potential to be transmitted to the transplant recipient.(1-3) The influence of these donor-transmitted infectious diseases on the outcome of organs transplantation could be immediately after transplantation or lasting several years afterward. However, the study focus on assessing donor with bacterial infection and related impact immediately after liver transplantation.

Any active bacterial infection in the donor may result in a lethal complication immediately after transplantation if bacteria are transmitted to the recipient during organ transplantation. Thus, the majority of transplantation surgeons are reluctant to transplant organs known to be infected by active bacteria. Specifically, the shortage of deceased donor is very stringent particularly in Oriental countries. In this study,

1
2
3
4 donors with bacterial infections were analyzed to assess the influence of an infected
5
6 donor on the outcome of deceased donor liver transplantation (DDLT). These results
7
8 provide additional information for the selection of deceased donors for liver
9
10 transplantation (LT).
11
12
13
14
15
16
17
18
19

20 **Methods**

21 *Patients*

22
23
24
25
26
27 A total of 285 consecutive DDLTs were performed during the period between January
28
29 1991 and February 2017 at the Transplantation Institute. All medical records of
30
31 donors and recipients were retrospectively reviewed under the approval from the
32
33 Institutional Review Board of Chang Gung Memorial Hospital. Of all LT, liver grafts
34
35 were procured from 248 donors including 81 donors from the national organ sharing
36
37 program and 167 donations from the institute. No executed prisoner organs were used
38
39
40
41 in this study. Liver graft donations and transplantations are illustrated in Figure 1.
42
43
44
45

46
47 Overall, 40 donors underwent split liver donation, and whole liver grafts were
48
49 procured from the 208 donors. Among whole liver donors, 13 donors had reduced size
50
51 liver grafts from a partial liver resected *ex vivo* in order to be implanted in recipients
52
53 with a relatively small abdominal cavity. Written informed consent was obtained from
54
55
56
57

1
2
3
4 all patients included.
5
6

7
8 ***Donor survey***
9

10
11 All potential donors were thoroughly checked by laboratory tests for hepatitis B and C
12
13 virus, human immunodeficiency virus (HIV), cytomegalovirus (CMV), Epstein-Barr
14
15 virus (EBV), toxoplasmosis and syphilis. Generally, chest radiography and
16
17 ultrasonography of the heart, liver and kidney would be routinely performed prior to
18
19 the donation of solid organs. With regard to the assessment of bacterial infection,
20
21 serial samples including bronchial aspirates, urine and blood were obtained for culture
22
23 before organs donation.
24
25
26
27
28
29

30
31 Generally, the potential donor should be hemodynamic stable with acceptable
32
33 cardiopulmonary function, absence of sepsis or uncontrollable bacterial infection and
34
35 without malignant neoplasm contraindicated for donation. Donor with virus including
36
37 hepatitis B, C virus, and HIV (after November 2016) were not contraindicated for
38
39 organs donation, but could be transplanted to recipient with same viral status. For
40
41 liver donation, the liver functional reserve of donor should be acceptable and less than
42
43 50% of hepatic parenchyma with steatosis. If the donor was eligible for organ
44
45 donation, transplantation surgeons would proceed to organ procurement after the
46
47 determination of brain death by specialists. There is no organs obtained from
48
49
50
51
52
53
54
55
56

1
2
3
4 non-heart beating donor in this study.
5
6

7 The decision to perform split liver grafts in two adult recipients was based on
8

9
10 preoperative hepatic sonography and an intraoperative assessment of the liver graft.
11

12
13 Transection of the hepatic parenchyma for split liver grafts was all performed *in situ*
14

15 as previously described.(4) Importantly, bile was routinely obtained through the
16

17
18 common bile duct for bacterial culture before flushing the biliary tree during liver
19

20
21 graft procurement from all donors.
22
23

24 25 ***Liver transplantation recipients*** 26

27
28 All graft implantations were performed using standard techniques without
29

30
31 venovenous bypass. Generally, prophylactic antibiotics were usually administered for
32

33
34 all recipients after transplantation unless the susceptibility profile required specific
35

36
37 antibiotics prior to transplantation. The selection of prophylactic antibiotics was based
38

39
40 on the illness of recipients, in which third-generation cephalosporins was given to
41

42
43 recipients with Model For End-Stage Liver Disease (MELD) scores less than 20; a
44

45
46 combination of vancomycin and imipenem/cilastatin was administered to recipients
47

48
49 with MELD scores above 20. Additionally, antibiotic treatment specific to the
50

51
52 recognized microorganisms from donor were also administered after transplantation
53

54
55 based on the result of donor's bacterial culture. The use of antifungal prophylaxis was
56

1
2
3
4 optional for recipients who had high risk of fungal infections such as longer
5
6 hospitalization before transplantation, longer operation time, massive blood loss and
7
8
9 blood transfusion during the operation. The immunosuppressive regimen for
10
11 recipients after transplantation mainly consisted of a combination of
12
13
14 methylprednisolone, tacrolimus and mycophenolate mofetil, adjusted based on the
15
16
17 clinical assessment of the recipient.
18
19

20 21 ***Outcomes and statistical analysis*** 22

23
24
25 Recipients were categorized into two groups: Group I consisted of recipients
26
27
28 transplanted with a graft procured from a donor with a positive bacterial culture, and
29
30
31 Group II included recipients who obtained a graft from a donor without evidence of
32
33
34 bacterial infection. Bacterial infection was intensively monitored using samples from
35
36
37 the blood, drainage tubes and catheters for all recipients after LT. Microorganisms that
38
39
40 grew in all cultures within 30 days after LT were recorded and assessed for bacterial
41
42
43 infection transmission from donor. The recipient's outcome measure was overall
44
45
46 survival (OS), which was calculated from the date of LT to the date of death or the
47
48
49 end of this study. Survival curves were constructed by the Kaplan-Meier method, and
50
51
52 further compared by the log rank test. Comparison of continuous variables were
53
54
55 performed by Student's t test, and categorical variables were compared by the
56
57
58
59
60

1
2
3
4 chi-square or Fisher's exact test as appropriate. All data were analyzed using the
5
6 statistical software SPSS version 20.0 (IBM Inc., Armonk, NY, USA) for Windows. A
7
8
9 p -value of < 0.05 was defined as statistically significant.
10

11 12 13 ***Patient and public involvement statement*** 14

15
16
17 This study analyzed a retrospective data review. There was no patient or public
18
19 involvement in this study including in the design, recruitment, and conduct of the
20
21
22 study.
23
24
25
26
27
28
29

30 31 32 33 **Results** 34

35 36 37 ***Donor features*** 38

39
40 All donors were donation after brain death; the 248 donors consisted of 174 males and
41
42 74 females. The median age of the donors was 40 years old, and ranged from 9 to 75
43
44 years old. The major causes of brain death were cerebrovascular accidents in 137
45
46 donors (55.2%) and head injury in 48 donors (19.4%). The median duration of stay in
47
48 the intensive care unit before donation was 3 days (ranging from 1 to 95 days).
49

50
51 Overall, 78 donors (31.5%) had positive bacterial culture samples, in which 3 (1.2%)
52
53
54 of them were with triple site positives, 13 (5.2%) were double site positives, and 62
55
56
57

(25%) were only single site positive (Fig. 2). Most positive bacterial cultures were from bronchial aspirates of sputum, which were noted in 66 donors that accounted for 26.6% of all donors and 84.6% of donors with positive bacterial infections. Additionally, bacterial growth was detected in 13 donors (5.2%) from blood cultures, 16 donors (6.5%) from urine cultures, and 7 donors (2.8%) from bile cultures.

Microorganisms in donor cultures

All positive bacterial cultures derived from donors are described in Table 1. A total of 21 bacterial species were identified, including 9 Gram-positive, 11 Gram-negative, and 1 Gram-variable. Among these, the three most common bacteria were *Klebsiella pneumoniae* ($n=34$), *Staphylococcus aureus* ($n=32$), and *Escherichia coli* ($n=13$). *Coagulase-negative Staphylococcus* was the first ranked bacterium found in the blood cultures of 7 donors, and *Escherichia coli* was the most common bacterium found in the urine cultures of 8 donors. *Klebsiella pneumoniae* was isolated from 32 donor sputum cultures and 2 donor bile cultures. Additionally, *Pseudomonas aeruginosa*, a relative common nosocomial species, was cultivated from 10 donor sputum cultures.

Recipient outcomes

Among the 285 DDLTs, 98 recipients (Group I) obtained grafts from 78 donors with positive bacterial cultures, while the remaining 187 recipients (Group II) were

transplanted with grafts from 170 donors who had no evidence of bacterial infection.

The clinical characteristics of recipients are summarized and compared in Table 2.

The majority of clinical features were similar between the two groups. However, the mean recipient age in Group I was significantly greater than that of Group II recipients ($p = 0.002$), and a significantly higher ratio of Group II recipients received whole liver grafts for transplantation ($p = 0.0002$). Moreover, group I patients had relative higher ratio of comorbidity as compared with Group II patients at the time of transplantation. ($p = 0.0414$) Importantly, the rates of bacterial growth from blood cultures and hospital mortality within 30 days after LT were not significantly different between the two groups. Overall, 159 (55.8%) patients were still alive by the end of the study, including 57 (58.2%) patients in Group I and 102 (54.5%) patients in Group II.

In Group I, only one recipient (1.02%) had *Acinetobacter baumannii* detected in a blood culture after LT, which was the same bacterium cultured from the donor's sputum prior to organ donation. The recipient was indicated for LT due to hepatitis B virus-related end stage liver cirrhosis, and obtained a right liver graft from a split liver donation. However, no evidence of *Acinetobacter baumannii* growth was noted in the blood culture in the other recipient who received a left liver graft from the same donor.

The groups of patients who obtained grafts from donor with and without bacterial

1
2
3
4 infection were compared and similar outcomes were found between the two groups
5
6 (Fig. 3, $p = 0.9746$). The analysis of the survival curves showed that the overall
7
8
9 survival rates at one and three years were 73.5% and 69.2% in Group I recipients,
10
11
12 while the corresponding values were 68.8% and 62.4% in Group II recipients.
13
14
15
16
17
18
19

20 **Discussion**

21
22
23 Although LT is currently considered the definitive treatment for individuals with
24
25 end-stage liver disease, unexpected transmission of infections from the donor to the
26
27 recipient remains a major concern. Although rare, complication related to
28
29 donor-derived infectious disease are associated with significant morbidity and
30
31 mortality. (3, 5-7) Among the types of donor-derived infections, bacterial transmission
32
33 from the donor could result in bacteremia immediately after transplantation and lead
34
35 to lethal complications. However, deceased donors are extremely rare in Oriental
36
37 countries, and the organ shortage for LT is exceptionally large as compared with
38
39 Western countries.(8, 9) Therefore, every donor should be carefully judged for organ
40
41 transplantation. This study analyzed donors in terms of bacterial infections in the
42
43 setting of scarce organ donation. The results show that the incidence of
44
45 donor-transmitted bacterial infections was very low, suggesting that donors with a
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 bacterial infection should not be excluded as organ donors for LT.
5
6

7 Generally, bacteria are the most common cause of infections in LT recipients.
8
9

10 However, opportunistic infections are generally uncommon in the first 1-4 weeks after
11
12 transplantation, depending on the recipient's net state of immunity. Thus, unexplained
13
14 early infections in this period are generally associated with surgery-related
15
16 complications or donor-derived infections. This study examined all recipient blood
17
18 cultures for bacteria within 30 days after LT to match the donor's bacterial infection.
19
20
21
22

23 In line with previous reports, the incidence of possible bacterial transmission from the
24
25 donor was very low.(10, 11) Only one recipient's blood culture had the same
26
27 bacterium as the donor, and accounted for only 1.02% of all recipients in the current
28
29 study.
30
31
32
33
34
35

36 *Acinetobacter baumannii* is a typical Gram-negative bacterium that can be an
37
38 opportunistic pathogen affecting patients with compromised immune systems.(12, 13)
39
40

41 However, the recipient who obtained the left liver graft from the same donor had no
42
43 evidence of this bacterium in their blood cultures after LT. Therefore, the recipient's
44
45 pathogen could be a hospital-derived nosocomial infection instead of transmission
46
47 from donor. Meanwhile, liver grafts are usually flushed with organ preserving
48
49 solution during organ procurement, and re-perfused with more than 1500 ml/min of
50
51
52
53
54
55
56

1
2
3
4 the recipient's blood after graft implantation. As such, bacteria within the liver graft
5
6 are likely to be diluted by these process, and the chance of donor-derived bacterial
7
8 infection in the recipient is very low.
9
10

11
12
13 However, the possibility of potential donor with severe bacterial infections such as
14
15 *Acinetobacter baumannii*, *vancomycin resistance Escherichia coli (VRE)*, or
16
17 *multi-drug resistant bacteria* might be existed. These antimicrobial resistance bacteria
18
19 were mostly detected in patients with severe illness or compromised immune systems,
20
21 and thus they might be unacceptable for organ donation because of poor general
22
23 condition. Although the usage of organs from donors infected with drug-resistance
24
25 bacteria remains uncertain, the urgent demand for organs perhaps would led to the use
26
27 of organs from these donors for specific recipients based on the urgency of the need
28
29 for transplantation. Nonetheless, the study was limited by its small number of patients,
30
31 in which the impact of the drug-resistance bacteria on the outcome of DDLT could not
32
33 be truly reflected. Therefore, further information from a larger cohort study to clarify
34
35 the influence of drug-resistance bacteria on organs transplantation is required in the
36
37 future.
38
39
40
41
42
43
44
45
46
47
48
49

50 Our data are similar to previous reports showing that the highest positive rate of
51
52 bacterial culture of the donor was from sputum cultures.(11, 14) The most common
53
54
55
56
57
58
59
60

1
2
3
4 pathogens cultivated from bronchial aspirates of the donors in this study were
5
6 *Klebsiella pneumoniae* and *Staphylococcus aureus*. Both pathogens are members of
7
8 the normal flora of the body, and are frequently found in the respiratory tract and
9
10 skin.(15, 16) *Klebsiella* infections are mostly seen in people with a weakened immune
11
12 system or a nosocomial infection, and *Staphylococcus aureus* is not always
13
14 pathogenic. Additionally, *Escherichia coli* was the most common pathogen found in
15
16 the urine cultures of our donor, which might be related to either translocation from the
17
18 gastrointestinal tract or contamination with feces. Therefore, culture results from
19
20 donors that show these pathogens could be ignored so the donors are not excluded
21
22 from organ donation.
23
24
25
26
27
28
29
30

31
32
33 Importantly, each potential donor should be comprehensively screened for medical
34
35 conditions that may affect the recipient, which might include the presence of
36
37 transmissible disease, malignancies, or any other known condition that may be
38
39 transmitted by the donor organ. However, it is currently impossible to screen potential
40
41 donors for all potential pathogens during the narrow timeframe of the organ donation
42
43 process. Specifically, bacterial cultures of potential donors take time and may not
44
45 provide results prior to organ procurement for transplantation. Likewise, a donor may
46
47 have a bacterial infection that has been appropriately treated. Under such
48
49 circumstances, treatment of the recipient for the recognized infection immediately
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 after transplantation might be satisfactory.
5
6

7 The preventive strategy of universal prophylaxis is mainly rely on the clinical status
8
9
10 of the recipient. Generally, microorganisms transmitted from donors is not likely to
11
12
13 cause infectious complications in every recipient, and the risk of infection is mostly
14
15
16 associated with the patient's net state of immunity. Therefore, antimicrobial
17
18
19 prophylaxis should be adjusted based on the severity of recipient's illness, individual
20
21
22 exposures, and hospital epidemiology. Additionally, antimicrobial prophylaxis should
23
24
25 also be adjusted according to identified microorganisms from donors. As a result, it
26
27
28 can provide adequate coverage of bacterial infections cultured from donor and prevent
29
30
31 infectious complication related to transmission of donor-derived infectious diseases.
32

33 **Conclusions**

34
35
36 Although the study is limited by its retrospective entity in a single transplantation
37
38
39 center with a small number of patients, several marked observation might be helpful
40
41
42 in clinical practice. Additionally, available organ donor numbers lag behind current
43
44
45 and future needs, and this organ shortage has thus forced clinicians to expand the
46
47
48 donor pool by using donors with the risk of transmitting infectious diseases. The
49
50
51 annual deceased organ donation rate has recently increased to 12.3 per million
52
53
54 population in Taiwan, but the number of DDLTs is still not satisfactory, with an
55
56
57

1
2
3
4 average of 100 cases per year.(17) Many other counties may also encounter this
5
6 situation regarding deceased donor organ transplantation and LT. As a result, a
7
8 bacterial infection in the donor should not preclude the use of organs for
9
10 transplantation. Moreover, the possibility of bacterial transmission from the donor
11
12 seems to extremely low considering fluid dilution and the non-specific culture results.
13
14
15
16
17
18
19
20
21

22 **Author contributions:**

23 Study concept, design and drafting the manuscript: Kun-Ming Chan

24 Acquisition of data: Kun-Ming Chan, Tsung-Han Wu, Chih-Hsien Cheng, Chen-Fang
25 Lee, Ting-Jung Wu, Hong-Shiue Chou, Wei-Chen Lee

26
27 Critical revision of the manuscript for important intellectual content: Kun-Ming Chan,
28 Wei-Chen Lee
29
30

31 **Funding:** This research received no specific grant from any funding agency in the
32 public, commercial or not-for-profit sectors.
33
34
35

36 **Competing interests:** All authors have no conflict of interest.
37
38

39 **Patient consents:** Obtained.
40
41

42 **Ethics approval:** The Institutional Review Board of Chang Gung Memorial Hospital
43
44

45 (Approval No.: 98-3794B)
46
47
48

49 **Data sharing statement:** No additional data available.
50
51
52
53
54
55

56 **References**

1. Fishman JA. Infection in solid-organ transplant recipients. *N. Engl. J. Med* 2007;357:2601-2614.
2. Fishman JA. Infection in Organ Transplantation. *Am J Transplant* 2017;17:856-879.
3. Ison MG, Grossi P, Practice ASTIDCo. Donor-derived infections in solid organ transplantation. *Am J Transplant* 2013;13 Suppl 4:22-30.
4. Lee WC, Chan KM, Chou HS, Wu TJ, Lee CF, Soong RS, Wu TH, et al. Feasibility of split liver transplantation for 2 adults in the model of end-stage liver disease era. *Ann Surg* 2013;258:306-311.
5. Ison MG, Nalesnik MA. An update on donor-derived disease transmission in organ transplantation. *Am J Transplant* 2011;11:1123-1130.
6. Cerutti E, Stratta C, Romagnoli R, Serra R, Lepore M, Fop F, Mascia L, et al. Bacterial- and fungal-positive cultures in organ donors: clinical impact in liver transplantation. *Liver Transpl* 2006;12:1253-1259.
7. Lumberras C, Sanz F, Gonzalez A, Perez G, Ramos MJ, Aguado JM, Lizasoain M, et al. Clinical significance of donor-unrecognized bacteremia in the outcome of solid-organ transplant recipients. *Clin Infect Dis* 2001;33:722-726.
8. Lo CM. Deceased donation in Asia: challenges and opportunities. *Liver Transpl* 2012;18 Suppl 2:S5-7.
9. Wang TH, Lee PC, Chiang YJ. Taiwan's organ donation and transplantation: Observation from national registry point of view. *J Formos Med Assoc* 2017;116:649-651.
10. Outerelo C, Gouveia R, Mateus A, Cruz P, Oliveira C, Ramos A. Infected donors in renal transplantation: expanding the donor pool. *Transplant Proc* 2013;45:1054-1056.
11. Yuan X, Chen C, Zhou J, Han M, Wang X, Wang C, He X. Organ Donation and Transplantation From Donors With Systemic Infection: A Single-Center Experience. *Transplant Proc* 2016;48:2454-2457.
12. Antunes LC, Visca P, Towner KJ. *Acinetobacter baumannii*: evolution of a global pathogen. *Pathog Dis* 2014;71:292-301.
13. Yeom J, Shin JH, Yang JY, Kim J, Hwang GS. (1)H NMR-based metabolite profiling of planktonic and biofilm cells in *Acinetobacter baumannii* 1656-2. *PLoS One* 2013;8:e57730.
14. Paredes D, Gamba MP, Cervera C, Linares L, Almela M, Rodriguez C, Ruiz A, et al. Characterization of the organ donor with bacteremia. *Transplant Proc* 2007;39:2083-2085.
15. Kluytmans J, van Belkum A, Verbrugh H. Nasal carriage of *Staphylococcus aureus*: epidemiology, underlying mechanisms, and associated risks. *Clin Microbiol Rev*

1
2
3 1997;10:505-520.

4 16. Podschun R, Ullmann U. Klebsiella spp. as nosocomial pathogens: epidemiology,
5 taxonomy, typing methods, and pathogenicity factors. Clin Microbiol Rev
6 1998;11:589-603.

7
8 17. Wang TH, Chang YP, Chiang WL. Improving Donation Rates in Taiwan.
9 Transplantation 2016;100:2235-2237.
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52

53 **Table 1.** Microorganisms cultured from donors.
54
55
56
57
58
59
60

Micro-organisms	Bacterial cultures				Total
	Sputum	Urine	Blood	Bile	
Gram-positive bacteria					
<i>Staph.aureus</i>	31	-	1	-	32
<i>coagulase-negative staphylococcus</i>	-	-	7	1	8
<i>Enterococcus faecalis</i>	-	5	1	-	6
<i>staphylococcus</i>	1	-	2	-	3
<i>Streptococcus pneumoniae</i>	3	-	-	-	3
<i>Staph.epidermidis</i>	-	1	1	-	2
<i>Aerococcus</i>	-	-	-	1	1
<i>Enterococcus faecium</i>	-	-	-	1	1
<i>Propionibacterium acnes</i>	-	-	-	1	1
Gram-negative bacteria					
<i>Klebsiella pneumoniae</i>	32	-	-	2	34
<i>Escherichia coli</i>	4	8	-	1	13
<i>Pseudomonas aeruginosa</i>	10	2	-	-	12
<i>Haemophilus influenzae</i>	8	-	-	-	8
<i>Enterobacter cloacae</i>	4	3	-	-	7
<i>Acinetobacter baumannii</i>	5	-	1	-	6
<i>Stenotrophomonas maltophilia</i>	2	2	1	1	6
<i>Enterobacter aerogenes</i>	4	-	1	-	5
<i>Veillonella sp</i>	-	-	2	-	2
<i>Proteus mirabilis</i>	2	-	-	-	2
<i>Serratia marcescens</i>	2	-	-	-	2
other					
<i>Gardnerella vaginalis</i>	-	1	-	-	1
Number represent number of patients					

Table 2. Clinical characteristics of patients with deceased donor liver transplantation.

Characteristics	Donor with positive bacterial cultures		<i>p</i> value
	Group I: Yes, <i>n</i> =98	Group II: No, <i>n</i> =187	
Age, median (range)	52 (33 – 65)	48 (1 – 67)	0.002
Sex (Male:Female)	77:21	132:55	0.160
Hepatitis status			0.403
Hepatitis B positive	51 (52.0%)	110 (58.8%)	
Hepatitis C positive	21 (21.4%)	27 (14.5%)	
Hepatitis B, C positive	3 (3.1%)	9 (4.8%)	
None	23 (23.5%)	41 (21.9%)	
Comorbidity			0.0414
Diabetic Mellitus	13 (13.3%)	14 (7.5%)	
Hypertension	12 (12.2%)	12 (6.4%)	
Chronic renal disease	5 (5.1%)	5 (2.7%)	
Heart disease	3 (3.1%)	0	
Others	3 (3.1%)	6 (3.2%)	
No	72 (73.5%)	157 (84.0%)	
Indication of LT			0.147
Alcoholic Liver cirrhosis	16 (16.3%)	10 (5.4%)	
Virus-related liver cirrhosis	40 (40.8%)	98 (52.4%)	
Hepatocellular carcinoma	32 (32.7%)	46 (24.6%)	
Others	10 (10.2%)	33 (17.6%)	
MELD score, median (range)	21 (7 – 40)	23 (7 – 40)	0.673
Type of grafts			0.0002
Whole liver graft	53 (54.1%)	142 (75.9%)	
Partial liver graft*	45 (45.9%)	45 (24.1%)	
Blood culture after LT (30days)			0.173
Positive bacterial growth	11 (11.2%)	12 (6.4%)	
Negative bacterial growth	87 (88.8%)	175 (93.6%)	
Patient outcomes			0.849
Hospital Mortality (30days)	11 (11.2%)	23 (12.3%)	
Graft dysfunction	0	4 (2.1%)	
Postoperative hemorrhage	2 (2.0%)	5 (2.7%)	
Severe bacterial infections	4 (4.1%)	8 (4.3%)	
Acute rejections	3 (3.1%)	4 (2.1%)	
Others	2 (2.0%)	2 (1.1%)	
Death	30 (30.6%)	62 (33.2%)	
Alive	57 (58.2%)	102 (54.5%)	

LT, liver transplantation; MELD, Model for End-stage Liver Disease. *partial liver grafts

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

included split liver and reduced size liver grafts.

For peer review only

Figure legend

1
2
3
4 **Figure 1.** Flow diagram of organ donors and liver transplantations assessed in this
5
6 study.
7
8
9

10
11
12
13 **Figure 2.** The rate of positive bacterial cultures in donors.
14
15

16
17
18 **Figure 3.** Comparison of cumulative overall survival for the patients showing no
19 significant difference between the two groups. Group I (···), Group II (—).
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 1

45x25mm (300 x 300 DPI)




Figure 2

44x24mm (300 x 300 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 3

30x17mm (300 x 300 DPI)

Reporting checklist for cohort study.

Based on the STROBE cohort guidelines.

Instructions to authors

Complete this checklist by entering the page numbers from your manuscript where readers will find each of the items listed below.

Your article may not currently address all the items on the checklist. Please modify your text to include the missing information. If you are certain that an item does not apply, please write "n/a" and provide a short explanation.

Upload your completed checklist as an extra file when you submit to a journal.

In your methods section, say that you used the STROBE cohort reporting guidelines, and cite them as:

von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: guidelines for reporting observational studies.

		Reporting Item	Page Number
Title	#1a	Indicate the study's design with a commonly used term in the title or the abstract	1
Abstract	#1b	Provide in the abstract an informative and balanced summary of what was done and what was found	2,3
Background / rationale	#2	Explain the scientific background and rationale for the investigation being reported	5
Objectives	#3	State specific objectives, including any prespecified hypotheses	5,6
Study design	#4	Present key elements of study design early in the paper	5,6
Setting	#5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	6,7
Eligibility criteria	#6a	Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up.	6,7

1		#6b	For matched studies, give matching criteria and number of	8,9
2			exposed and unexposed	
3				
4	Variables	#7	Clearly define all outcomes, exposures, predictors, potential	8,9
5			confounders, and effect modifiers. Give diagnostic criteria, if	
6			applicable	
7				
8				
9				
10	Data sources /	#8	For each variable of interest give sources of data and details of	8,9
11	measurement		methods of assessment (measurement). Describe	
12			comparability of assessment methods if there is more than one	
13			group. Give information separately for for exposed and	
14			unexposed groups if applicable.	
15				
16				
17				
18	Bias	#9	Describe any efforts to address potential sources of bias	7
19				
20	Study size	#10	Explain how the study size was arrived at	6
21				
22				
23	Quantitative	#11	Explain how quantitative variables were handled in the	8,9
24	variables		analyses. If applicable, describe which groupings were chosen,	
25			and why	
26				
27				
28	Statistical	#12a	Describe all statistical methods, including those used to control	8,9
29	methods		for confounding	
30				
31				
32		#12b	Describe any methods used to examine subgroups and	8,9
33			interactions	
34				
35				
36		#12c	Explain how missing data were addressed	See note
37				1
38				
39				
40		#12d	If applicable, explain how loss to follow-up was addressed	See note
41				2
42				
43				
44		#12e	Describe any sensitivity analyses	See note
45				3
46				
47	Participants	#13a	Report numbers of individuals at each stage of study—eg	9
48			numbers potentially eligible, examined for eligibility, confirmed	
49			eligible, included in the study, completing follow-up, and	
50			analysed. Give information separately for for exposed and	
51			unexposed groups if applicable.	
52				
53				
54				
55				
56		#13b	Give reasons for non-participation at each stage	n/a
57				
58		#13c	Consider use of a flow diagram	See note
59				
60				

1			4
2			
3	Descriptive data	#14a	9-11
4		Give characteristics of study participants (eg demographic,	
5		clinical, social) and information on exposures and potential	
6		confounders. Give information separately for exposed and	
7		unexposed groups if applicable.	
8			
9		#14b	See note
10		Indicate number of participants with missing data for each	
11		variable of interest	5
12			
13		#14c	11
14		Summarise follow-up time (eg, average and total amount)	
15	Outcome data	#15	11
16		Report numbers of outcome events or summary measures	
17		over time. Give information separately for exposed and	
18		unexposed groups if applicable.	
19			
20	Main results	#16a	See note
21		Give unadjusted estimates and, if applicable, confounder-	
22		adjusted estimates and their precision (eg, 95% confidence	
23		interval). Make clear which confounders were adjusted for and	6
24		why they were included	
25			
26		#16b	n/a
27		Report category boundaries when continuous variables were	
28		categorized	
29			
30		#16c	n/a
31		If relevant, consider translating estimates of relative risk into	
32		absolute risk for a meaningful time period	
33			
34	Other analyses	#17	n/a
35		Report other analyses done—e.g., analyses of subgroups and	
36		interactions, and sensitivity analyses	
37			
38	Key results	#18	12
39		Summarise key results with reference to study objectives	
40			
41	Limitations	#19	15
42		Discuss limitations of the study, taking into account sources of	
43		potential bias or imprecision. Discuss both direction and	
44		magnitude of any potential bias.	
45			
46	Interpretation	#20	15
47		Give a cautious overall interpretation considering objectives,	
48		limitations, multiplicity of analyses, results from similar studies,	
49		and other relevant evidence.	
50			
51	Generalisability	#21	15
52		Discuss the generalisability (external validity) of the study	
53		results	
54			
55	Funding	#22	16
56		Give the source of funding and the role of the funders for the	
57		present study and, if applicable, for the original study on which	
58			
59			
60			

the present article is based

Author notes

1. n/a, no missing data
2. n/a, no loss follow-up patient
3. n/a, not applicable
4. 6, figure 1
5. n/a, no missing data
6. n/a, not applicable

The STROBE checklist is distributed under the terms of the Creative Commons Attribution License CC-BY. This checklist was completed on 30. April 2018 using <http://www.goodreports.org/>, a tool made by the [EQUATOR Network](#) in collaboration with [Penelope.ai](#)

BMJ Open

Impact of donor with evidence of bacterial infections on deceased donor liver transplantation-A retrospective observational cohort study in Taiwan

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-023908.R2
Article Type:	Research
Date Submitted by the Author:	05-Oct-2018
Complete List of Authors:	Chan, Kun-Ming; Chang Gung Memorial Hospital Linkou Branch, General Surgery Cheng, Chih-Hsien; Chang Gung Memorial Hospital Linkou Branch, General Surgery Wu, Tsung-Han; Chang Gung Memorial Hospital Linkou Branch, General Surgery Lee, Chen-Fang; Chang Gung Memorial Hospital Linkou Branch, General Surgery Wu, Ting-Jung; Chang Gung Memorial Hospital Linkou Branch, General Surgery Chou, Hong-Shiue; Chang Gung Memorial Hospital Linkou Branch, General Surgery Lee, Wei-Chen; Chang Gung Memorial Hospital Linkou Branch, General Surgery
Primary Subject Heading:	Surgery
Secondary Subject Heading:	Gastroenterology and hepatology, Infectious diseases, Medical management
Keywords:	Transplant medicine < INTERNAL MEDICINE, Transplant surgery < SURGERY, TRANSPLANT SURGERY

SCHOLARONE™
Manuscripts

1
2
3
4 **Title: Impact of donor with evidence of bacterial infections on**
5
6
7 **deceased donor liver transplantation-A retrospective observational**
8
9
10 **cohort study in Taiwan**
11
12
13
14

15 **Authors:** Kun-Ming Chan, M.D.^{1,2}, Chih-Hsien Cheng, M.D.¹, Tsung-Han Wu,
16 M.D.¹, Chen-Fang Lee, M.D.¹, Ting-Jung Wu, M.D.¹, Hong-Shiue Chou, M.D.¹, Wei-
17 Chen Lee, M.D.¹
18
19

20
21
22 **Institutions:**

23
24 ¹Department of General Surgery & Department of Organs Transplantation Institute,
25 Chang Gung Memorial Hospital at Linkou, Chang Gung University College of
26 Medicine, Taoyuan, Taiwan.
27
28

29
30
31 **²Correspondence information: Kun-Ming Chan, MD**

32 Department of General Surgery & Department of Organs Transplantation Institute,
33 Chang Gung Memorial Hospital at Linkou,
34 Chang Gung University College of Medicine, Taoyuan, Taiwan.
35
36 5 Fu-Hsing Street, Kwei-Shan District, Taoyuan City 33305, Taiwan
37
38

39 **E-mail:** chankunming@adm.cgmh.org.tw
40
41
42
43

44 **Running head:** donor bacterial infection on DDLT
45
46
47
48
49
50

51 **Words count:** 2801 words; 2 tables, 3 figures
52
53
54
55
56
57
58
59
60

Abstract

Objective: The shortage of available donor organs is an unsolvable concern leading to an expansion in the donor criteria for organ transplantation. Here, we describe our experience and assess the outcomes in recipients who obtained a graft from a donor with bacterial infections in deceased donor liver transplantation (DDLT).

Methods: All DDLTs between January 1991 and February 2017 were retrospectively reviewed. Patients were categorized into two groups based on recipients who obtained a graft from a donor with (Group I) or without (Group II) evidence of bacterial infections. Outcomes and bacterial infections were compared between the two groups of recipients.

Results: Overall, a total of 285 DDLTs were performed from 248 donors consisting of 48 split liver grafts and 208 whole liver grafts. Of those, 98 recipients (Group I, 34.3%) were transplanted with a graft from 78 donors with positive bacterial cultures. Donor sputum cultures had the highest rate of positive bacterial growth, accounting for 26.6% of donors. Overall survival was not significantly different between the two groups. ($p=0.9746$) The overall survival rates at one and three years were 73.5% and 69.2% in the Group I recipients *versus* 68.8% and 62.4% in the Group II recipients. Importantly, no hospital mortality was related to donor-derived bacterial infections.

1
2
3
4 **Conclusion:** Transmission of bacteria from the donor to the recipient is infrequent in
5
6
7 DDLT. Therefore, potential donors with positive bacterial infections should not be
8
9
10 excluded for organ transplantation in order to increase organ availability and
11
12
13 ameliorate the organ shortage.
14

15
16
17
18
19
20
21 **Keywords:** deceased donor; bacterial infection; transmission; liver transplantation;
22
23
24 outcomes
25
26
27
28
29
30
31

32 **Strengths and limitations of this study**

33
34
35

- 36 1. The shortage of deceased organ donors is stringent in Oriental Countries as
37
38 compared with Western Countries, and thus every donor should be carefully judged
39
40
41 for organ transplantation in order to achieve greatest effectiveness.
42
43
44
- 45 2. This study enrolled 285 deceased donor liver transplantation in the setting of scarce
46
47
48 organ donation, and analyzed the influence of donors with evidence of bacterial
49
50
51 infections on liver transplantation.
52
53
54
- 55 3. The results show that the incidence of donor-transmitted bacterial infections was
56
57
58
59 very low, suggesting that donors with a bacterial infection should not be excluded as
60

1
2
3
4 organ donors for liver transplantation.
5
6
7

8 4. The study is limited by its retrospective entity in a single transplantation center
9

10 with a small number of patients.
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Introduction

Organ transplantation is a promising alternative for the treatment of many end-stage diseases. However, the discrepancy between organ demand and donor availability is currently an unsolvable concern. Therefore, expanded donor criteria including older donors, circulatory death donors, or donors with mild diseases and so forth are increasingly used as donors for organ transplantation. Subsequently, there is a high possibility of the transmission of unwanted infectious diseases following organ donation. Infectious microbes including viruses, bacteria, parasites and fungi that are present in organ donors have the potential to be transmitted to the transplant recipient.⁽¹⁻³⁾ The influence of these donor-transmitted infectious diseases on the outcome of organs transplantation could be immediately after transplantation or lasting several years afterward. However, the study focus on assessing donor with bacterial infection and related impact immediately after liver transplantation. Any active bacterial infection in the donor may result in a lethal complication immediately after transplantation if bacteria are transmitted to the recipient during organ transplantation. Thus, the majority of transplantation surgeons are reluctant to transplant organs known to be infected by active bacteria. Specifically, the shortage of deceased donor is very stringent particularly in Oriental countries. In this study,

1
2
3
4 donors with bacterial infections were analyzed to assess the influence of an infected
5
6
7 donor on the outcome of deceased donor liver transplantation (DDLT). These results
8
9
10 might provide additional information for the selection of deceased donors for liver
11
12
13 transplantation (LT).
14

21 **Methods**

25 *Patients*

26
27
28
29 A total of 285 consecutive DDLTs were performed during the period between January
30
31
32 1991 and February 2017 at the Transplantation Institute. All medical records of
33
34
35 donors and recipients were retrospectively reviewed under the approval from the
36
37
38 Institutional Review Board of Chang Gung Memorial Hospital. Of all LT, liver grafts
39
40
41 were procured from 248 donors including 81 donors from the national organ sharing
42
43
44 program and 167 donations from the institute. No executed prisoner organs were used
45
46
47 in this study. Liver graft donations and transplantations are illustrated in Figure 1.
48

49
50 Overall, 40 donors underwent split liver donation, and whole liver grafts were
51
52
53 procured from the 208 donors. Among whole liver donors, 13 donors had reduced size
54
55
56 liver grafts from a partial liver resected *ex vivo* in order to be implanted in recipients
57
58
59 with a relatively small abdominal cavity. Written informed consent was obtained from
60

1
2
3
4 all patients included.
5
6
7

8 ***Donor survey*** 9

10
11 All potential donors were thoroughly checked by laboratory tests for hepatitis B and C
12
13 virus, human immunodeficiency virus (HIV), cytomegalovirus (CMV), Epstein-Barr
14
15 virus (EBV), toxoplasmosis and syphilis. Generally, chest radiography and
16
17 ultrasonography of the heart, liver and kidney would be routinely performed prior to
18
19 the donation of solid organs. With regard to the assessment of bacterial infection,
20
21 serial samples including bronchial aspirates, urine and blood were obtained for culture
22
23 before organs donation.
24
25
26
27
28
29
30
31
32
33

34 Generally, the potential donor should be hemodynamic stable with acceptable
35
36 cardiopulmonary function, absence of sepsis or uncontrollable bacterial infection and
37
38 without malignant neoplasm contraindicated for donation. Donor with virus including
39
40 hepatitis B, C virus, and HIV (after November 2016) were not contraindicated for
41
42 organs donation, but could be transplanted to recipient with same viral status. For
43
44 liver donation, the liver functional reserve of donor should be acceptable and less than
45
46 50% of hepatic parenchyma with steatosis. If the donor was eligible for organ
47
48 donation, transplantation surgeons would proceed to organ procurement after the
49
50 determination of brain death by specialists. There is no organs obtained from non-
51
52
53
54
55
56
57
58
59
60

1
2
3
4 heart beating donor in this study.
5
6
7

8 The decision to perform split liver grafts in two adult recipients was based on
9
10 preoperative hepatic sonography and an intraoperative assessment of the liver graft.
11
12

13 Transection of the hepatic parenchyma for split liver grafts was all performed *in situ*
14
15 as previously described.⁽⁴⁾ Importantly, bile was routinely obtained through the
16
17 common bile duct for bacterial culture before flushing the biliary tree during liver
18
19 graft procurement from all donors.
20
21
22
23
24

25 26 27 ***Liver transplantation recipients*** 28

29
30 All graft implantations were performed using standard techniques without
31
32 venovenous bypass. Generally, prophylactic antibiotics were usually administered for
33
34 all recipients after transplantation unless the susceptibility profile required specific
35
36 antibiotics prior to transplantation. The selection of prophylactic antibiotics was based
37
38 on the illness of recipients, in which third-generation cephalosporins was given to
39
40 recipients with Model For End-Stage Liver Disease (MELD) scores less than 20; a
41
42 combination of vancomycin and imipenem/cilastatin was administered to recipients
43
44 with MELD scores above 20. Additionally, antibiotic treatment specific to the
45
46 recognized microorganisms from donor were also administered after transplantation
47
48 based on the result of donor's bacterial culture. The use of antifungal prophylaxis was
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 optional for recipients who had high risk of fungal infections such as longer
5
6
7 hospitalization before transplantation, longer operation time, massive blood loss and
8
9
10 blood transfusion during the operation. The immunosuppressive regimen for
11
12
13 recipients after transplantation mainly consisted of a combination of
14
15
16 methylprednisolone, tacrolimus and mycophenolate mofetil, and adjusted based on
17
18
19 the clinical assessment of the recipient.
20
21
22

23 ***Outcomes and statistical analysis***

24
25
26
27 Recipients were categorized into two groups: Group I consisted of recipients
28
29
30 transplanted with a graft procured from a donor with a positive bacterial culture, and
31
32
33 Group II included recipients who obtained a graft from a donor without evidence of
34
35
36 bacterial infection. Bacterial infection was intensively monitored using samples from
37
38
39 the blood, drainage tubes and catheters for all recipients after LT. Microorganisms
40
41
42 that grew in all cultures within 30 days after LT were recorded and assessed for
43
44
45 bacterial infection transmission from donor. The recipient's outcome measure was
46
47
48 overall survival (OS), which was calculated from the date of LT to the date of death
49
50
51 or the end of this study. Survival curves were constructed by the Kaplan-Meier
52
53
54 method, and further compared by the log rank test. All variables were assessed for
55
56
57 multivariate analyses using the Cox hazards regression model. Comparison of
58
59
60

1
2
3
4 continuous variables were performed by Student's t test, and categorical variables
5
6
7 were compared by the chi-square or Fisher's exact test as appropriate. All data were
8
9
10 analyzed using the statistical software SPSS version 20.0 (IBM Inc., Armonk, NY,
11
12
13 USA) for Windows. A *p*-value of < 0.05 was defined as statistically significant.
14
15

16 17 ***Patient and public involvement statement*** 18

19
20
21 This study analyzed a retrospective data review. There was no patient or public
22
23
24 involvement in this study including in the design, recruitment, and conduct of the
25
26
27 study.
28
29
30
31
32
33
34

35 **Results** 36 37

38 39 ***Donor features*** 40 41 42

43 All donors were donation after brain death; the 248 donors consisted of 174 males and
44
45
46 74 females. The median age of the donors was 40 years old, and ranged from 9 to 75
47
48
49 years old. The major causes of brain death were cerebrovascular accidents in 137
50
51
52 donors (55.2%) and head injury in 48 donors (19.4%). The median duration of stay in
53
54
55 the intensive care unit before donation was 3 days (ranging from 1 to 95 days).
56
57
58 Overall, 78 donors (31.5%) had positive bacterial culture samples, in which 3 (1.2%)
59
60

1
2
3
4 of them had triple site positives, 13 (5.2%) had double site positives, and 62 (25%)

5
6
7 had only single site positive (Fig. 2). Most positive bacterial cultures were from

8
9
10 bronchial aspirates of sputum, which were noted in 66 donors that accounted for

11
12
13 26.6% of all donors and 84.6% among donors with positive bacterial infections.

14
15
16 Additionally, bacterial growth was detected from blood cultures in 13 donors (5.2%),

17
18
19 from urine cultures in 16 donors (6.5%), and from bile cultures in 7 donors (2.8%).

20 21 22 23 ***Microorganisms in donor cultures***

24
25
26 All positive bacterial cultures derived from donors are described in Table 1. A total of

27
28
29 21 bacterial species were identified, including 9 Gram-positive, 11 Gram-negative,

30
31
32 and 1 Gram-variable. Among these, the three most common bacteria were *Klebsiella*

33
34
35 *pneumoniae* (n=34), *Staphylococcus aureus* (n=32), and *Escherichia coli* (n=13).

36
37
38 *Coagulase-negative Staphylococcus* was the first ranked bacterium found in the blood

39
40
41 cultures of 7 donors, and *Escherichia coli* was the most common bacterium found in

42
43
44 the urine cultures of 8 donors. *Klebsiella pneumoniae* was isolated from 32 donor

45
46
47 sputum cultures and 2 donor bile cultures. Additionally, *Pseudomonas aeruginosa*, a

48
49
50 relative common nosocomial species, was cultivated from 10 donor sputum cultures.

51 52 53 54 ***Recipient outcomes***

55
56
57 Among the 285 DDLTs, 98 recipients (Group I) obtained grafts from 78 donors with

1
2
3
4 positive bacterial cultures, while the remaining 187 recipients (Group II) were
5
6
7 transplanted with grafts from 170 donors who had no evidence of bacterial infection.
8
9

10 The clinical characteristics of recipients are summarized and compared in Table 2.
11

12
13 The majority of clinical features were similar between the two groups. However, the
14
15
16 mean recipient age in Group I was significantly greater than that of Group II
17
18 recipients ($p = 0.002$), and a significantly higher ratio of Group II recipients received
19
20 whole liver grafts for transplantation ($p = 0.0002$). Moreover, group I patients had
21
22 relative higher ratio of comorbidity as compared with Group II patients at the time of
23
24 transplantation. ($p = 0.0414$) Importantly, the rates of bacterial growth from blood
25
26 cultures and hospital mortality within 30 days after LT were not significantly different
27
28
29 between the two groups. Overall, 159 (55.8%) patients were still alive by the end of
30
31 the study, including 57 (58.2%) patients in Group I and 102 (54.5%) patients in Group
32
33
34
35
36
37
38
39
40 II.

41
42
43
44 In Group I, only one recipient (1.02%) had *Acinetobacter baumannii* detected in a
45
46 blood culture after LT, which was the same bacterium cultured from the donor's
47
48 sputum prior to organ donation. The recipient was indicated for LT due to hepatitis B
49
50 virus-related end stage liver cirrhosis, and obtained a right liver graft from a split liver
51
52 donation. However, no evidence of *Acinetobacter baumannii* growth was noted in the
53
54 blood culture in the other recipient who received a left liver graft from the same
55
56
57
58
59
60

1
2
3
4 donor. Patients who obtained grafts from donor with and without bacterial infection
5
6
7 were compared, and similar outcomes were found between the two groups (Fig. 3, $p =$
8
9
10 0.9746). The analysis of the survival curves showed that the overall survival rates at
11
12
13 one and three years were 73.5% and 69.2% in Group I recipients, while the
14
15
16 corresponding values were 68.8% and 62.4% in Group II recipients. The hazard ratio
17
18
19 (HR) of donor with evidence of bacterial infection was 1.01 [$p = 0.956$, 95%
20
21
22 confidence interval (CI) = 0.69-1.47] for overall survival after transplantation, and the
23
24
25 adjusted HR were 0.80 ($p = 0.310$, 95% CI= 0.52-1.23) after adjusted for gender, age,
26
27
28 and comorbidity.
29

30
31
32 Additionally, a propensity score matching was performed to minimize the influence of
33
34
35 confounding factors between the two groups. According to the matching analysis,
36
37
38 there was also no significant differences between the two groups in terms of overall
39
40
41 survival. (Fig. 4, $p = 0.3443$) The 1- and 3-year OS was 73.5% and 62.2% for patients
42
43
44 in the group I, and 69.2% and 56.1%, respectively for patients in the group II.
45

46
47 Moreover, multivariate regression analysis showed that the presence of donor with
48
49
50 bacterial infection was not a significant prognostic factor affecting recipient's
51
52
53 outcome after liver transplantation as well. (Supplemental table 1).
54
55
56
57
58
59
60

Discussion

Although LT is currently considered the definitive treatment for individuals with end-stage liver disease, unexpected transmission of infections from the donor to the recipient remains a major concern. Although rare, complication related to donor-derived infectious disease are associated with significant morbidity and mortality. (3, 5-7) Among the types of donor-derived infections, bacterial transmission from the donor could result in bacteremia immediately after transplantation and lead to lethal complications. However, deceased donors are extremely rare in Oriental countries, and the organ shortage for LT is exceptionally large as compared with Western countries.(8, 9) Therefore, every donor should be carefully judged for organ transplantation. This study analyzed donors in terms of bacterial infections in the setting of scarce organ donation. The results show that the incidence of donor-transmitted bacterial infections was very low, suggesting that donors with a bacterial infection should not be excluded as organ donors for LT.

Generally, bacteria are the most common cause of infections in LT recipients.

However, opportunistic infections are generally uncommon in the first 1-4 weeks after transplantation, depending on the recipient's net state of immunity. Thus, unexplained early infections in this period are generally associated with surgery-related

1
2
3
4 complications or donor-derived infections. This study examined all recipient blood
5
6
7 cultures for bacteria within 30 days after LT to match the donor's bacterial infection.
8
9

10 In line with previous reports, the incidence of possible bacterial transmission from the
11
12 donor was very low.(10, 11) Only one recipient's blood culture had the same
13
14
15 bacterium as the donor, and accounted for only 1.02% of all recipients in the current
16
17
18 study.
19
20
21
22

23 *Acinetobacter baumannii* is a typical Gram-negative bacterium that can be an
24
25
26 opportunistic pathogen affecting patients with compromised immune systems.(12, 13)
27
28

29 However, the recipient who obtained the left liver graft from the same donor had no
30
31
32 evidence of this bacterium in their blood cultures after LT. Therefore, the recipient's
33
34
35 pathogen could be a hospital-derived nosocomial infection instead of transmission
36
37
38 from donor. Meanwhile, liver grafts are usually flushed with organ preserving
39
40
41 solution during organ procurement, and re-perfused with more than 1500 ml/min of
42
43
44 the recipient's blood after graft implantation. As such, bacteria within the liver graft
45
46
47 are likely to be diluted by these process, and the chance of donor-derived bacterial
48
49
50 infection in the recipient is very low.
51
52
53

54 However, the possibility of potential donor with severe bacterial infections such as

55
56
57 *Acinetobacter baumannii*, vancomycin resistance *Escherichia coli* (VRE), or multi-
58
59
60

1
2
3
4 *drug resistant bacteria* might be existed. These antimicrobial resistance bacteria were
5
6
7 mostly detected in patients with severe illness or compromised immune systems, and
8
9
10 thus they might be unacceptable for organ donation because of poor general
11
12
13 condition. Although the usage of organs from donors infected with drug-resistance
14
15
16 bacteria remains uncertain, the urgent demand for organs perhaps would led to the use
17
18
19 of organs from these donors for specific recipients based on the urgency of the need
20
21
22 for transplantation. Nonetheless, the study was limited by its small number of
23
24
25 patients, in which the impact of the drug-resistance bacteria on the outcome of DDLT
26
27
28 could not be truly reflected. Therefore, further information from a larger cohort study
29
30
31 to clarify the influence of drug-resistance bacteria on organs transplantation is
32
33
34 required in the future.

35
36
37
38 Our data are similar to previous reports showing that the highest positive rate of
39
40
41 bacterial culture of the donor was from sputum cultures.(11, 14) The most common
42
43
44 pathogens cultivated from bronchial aspirates of the donors in this study were
45
46
47 *Klebsiella pneumoniae* and *Staphylococcus aureus*. Both pathogens are members of
48
49
50 the normal flora of the body, and are frequently found in the respiratory tract and
51
52
53 skin.(15, 16) *Klebsiella* infections are mostly seen in people with a weakened immune
54
55
56 system or a nosocomial infection, and *Staphylococcus aureus* is not always
57
58
59 pathogenic. Additionally, *Escherichia coli* was the most common pathogen found in
60

1
2
3
4 the urine cultures of our donor, which might be related to either translocation from the
5
6
7 gastrointestinal tract or contamination with feces. Therefore, culture results from
8
9
10 donors that show these pathogens could be ignored so the donors are not excluded
11
12
13 from organ donation.

14
15
16
17 Importantly, each potential donor should be comprehensively screened for medical
18
19
20 conditions that may affect the recipient, which might include the presence of
21
22
23 transmissible disease, malignancies, or any other known condition that may be
24
25
26 transmitted by the donor organ. However, it is currently impossible to screen potential
27
28
29 donors for all potential pathogens during the narrow timeframe of the organ donation
30
31
32 process. Specifically, bacterial cultures of potential donors take time and may not
33
34
35 provide results prior to organ procurement for transplantation. Likewise, a donor may
36
37
38 have a bacterial infection that has been appropriately treated. Under such
39
40
41 circumstances, treatment of the recipient for the recognized infection immediately
42
43
44 after transplantation might be satisfactory.

45
46
47
48 The preventive strategy of universal prophylaxis is mainly rely on the clinical status
49
50
51 of the recipient. Generally, microorganisms transmitted from donors is not likely to
52
53
54 cause infectious complications in every recipient, and the risk of infection is mostly
55
56
57 associated with the patient's net state of immunity. Therefore, antimicrobial
58
59
60

1
2
3
4 prophylaxis should be adjusted based on the severity of recipient's illness, individual
5
6
7 exposures, and hospital epidemiology. Additionally, antimicrobial prophylaxis should
8
9
10 also be adjusted according to identified microorganisms from donors. As a result, it
11
12
13 can provide adequate coverage of bacterial infections cultured from donor and prevent
14
15
16 infectious complication related to transmission of donor-derived infectious diseases.

19 **Conclusions**

20
21
22
23 Although the study is limited by its retrospective entity in a single transplantation
24
25
26 center with a small number of patients, several marked observation might be helpful
27
28
29 in clinical practice. Additionally, available organ donor numbers lag behind current
30
31
32 and future needs, and this organ shortage has thus forced clinicians to expand the
33
34
35 donor pool by using donors with the risk of transmitting infectious diseases. The
36
37
38 annual deceased organ donation rate has recently increased to 12.3 per million
39
40
41 population in Taiwan, but the number of DDLTs is still not satisfactory, with an
42
43
44 average of 100 cases per year.⁽¹⁷⁾ Many other counties may also encounter this
45
46
47 situation regarding deceased donor organ transplantation and LT. As a result, a
48
49
50 bacterial infection in the donor should not preclude the use of organs for
51
52
53 transplantation. Moreover, the possibility of bacterial transmission from the donor
54
55
56 seems to extremely low considering fluid dilution and the non-specific culture results.
57
58
59
60

Author contributions:

Study concept, design and drafting the manuscript: Kun-Ming Chan

Acquisition of data: Kun-Ming Chan, Tsung-Han Wu, Chih-Hsien Cheng, Chen-Fang Lee, Ting-Jung Wu, Hong-Shiue Chou, Wei-Chen Lee

Critical revision of the manuscript for important intellectual content: Kun-Ming Chan, Wei-Chen Lee

Funding: This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests: All authors have no conflict of interest.

Patient consents: Obtained.

Ethics approval: The Institutional Review Board of Chang Gung Memorial Hospital

(Approval No.: 98-3794B)

Data sharing statement: No additional data available.

References

1. Fishman JA. Infection in solid-organ transplant recipients. *N. Engl. J. Med* 2007;357:2601-2614.
2. Fishman JA. Infection in Organ Transplantation. *Am J Transplant* 2017;17:856-879.
3. Ison MG, Grossi P, Practice ASTIDCo. Donor-derived infections in solid organ transplantation. *Am J Transplant* 2013;13 Suppl 4:22-30.
4. Lee WC, Chan KM, Chou HS, Wu TJ, Lee CF, Soong RS, Wu TH, et al. Feasibility of split liver transplantation for 2 adults in the model of end-stage liver disease era. *Ann Surg* 2013;258:306-311.
5. Ison MG, Nalesnik MA. An update on donor-derived disease transmission in

- organ transplantation. *Am J Transplant* 2011;11:1123-1130.
6. Cerutti E, Stratta C, Romagnoli R, Serra R, Lepore M, Fop F, Mascia L, et al. Bacterial- and fungal-positive cultures in organ donors: clinical impact in liver transplantation. *Liver Transpl* 2006;12:1253-1259.
7. Lumbreras C, Sanz F, Gonzalez A, Perez G, Ramos MJ, Aguado JM, Lizasoain M, et al. Clinical significance of donor-unrecognized bacteremia in the outcome of solid-organ transplant recipients. *Clin Infect Dis* 2001;33:722-726.
8. Lo CM. Deceased donation in Asia: challenges and opportunities. *Liver Transpl* 2012;18 Suppl 2:S5-7.
9. Wang TH, Lee PC, Chiang YJ. Taiwan's organ donation and transplantation: Observation from national registry point of view. *J Formos Med Assoc* 2017;116:649-651.
10. Outerelo C, Gouveia R, Mateus A, Cruz P, Oliveira C, Ramos A. Infected donors in renal transplantation: expanding the donor pool. *Transplant Proc* 2013;45:1054-1056.
11. Yuan X, Chen C, Zhou J, Han M, Wang X, Wang C, He X. Organ Donation and Transplantation From Donors With Systemic Infection: A Single-Center Experience. *Transplant Proc* 2016;48:2454-2457.
12. Antunes LC, Visca P, Towner KJ. *Acinetobacter baumannii*: evolution of a global pathogen. *Pathog Dis* 2014;71:292-301.
13. Yeom J, Shin JH, Yang JY, Kim J, Hwang GS. (1)H NMR-based metabolite profiling of planktonic and biofilm cells in *Acinetobacter baumannii* 1656-2. *PLoS One* 2013;8:e57730.
14. Paredes D, Gamba MP, Cervera C, Linares L, Almela M, Rodriguez C, Ruiz A, et al. Characterization of the organ donor with bacteremia. *Transplant Proc* 2007;39:2083-2085.
15. Kluytmans J, van Belkum A, Verbrugh H. Nasal carriage of *Staphylococcus aureus*: epidemiology, underlying mechanisms, and associated risks. *Clin Microbiol Rev* 1997;10:505-520.
16. Podschun R, Ullmann U. *Klebsiella* spp. as nosocomial pathogens: epidemiology, taxonomy, typing methods, and pathogenicity factors. *Clin Microbiol Rev* 1998;11:589-603.
17. Wang TH, Chang YP, Chiang WL. Improving Donation Rates in Taiwan. *Transplantation* 2016;100:2235-2237.

Table 1. Microorganisms cultured from donors.

Micro-organisms	Bacterial cultures				Total
	Sputum	Urine	Blood	Bile	
Gram-positive bacteria					
<i>Staph.aureus</i>	31	–	1	–	32
<i>coagulase-negative staphylococcus</i>	–	–	7	1	8
<i>Enterococcus faecalis</i>	–	5	1	–	6
<i>staphylococcus</i>	1	–	2	–	3
<i>Streptococcus pneumoniae</i>	3	–	–	–	3
<i>Staph.epidermidis</i>	–	1	1	–	2
<i>Aerococcus</i>	–	–	–	1	1
<i>Enterococcus faecium</i>	–	–	–	1	1
<i>Propionibacterium acnes</i>	–	–	–	1	1
Gram-negative bacteria					
<i>Klebsiella pneumoniae</i>	32	–	–	2	34
<i>Escherichia coli</i>	4	8	–	1	13
<i>Pseudomonas aeruginosa</i>	10	2	–	–	12
<i>Haemophilus influenzae</i>	8	–	–	–	8
<i>Enterobacter cloacae</i>	4	3	–	–	7
<i>Acinetobacter baumannii</i>	5	–	1	–	6
<i>Stenotrophomonas maltophilia</i>	2	2	1	1	6
<i>Enterobacter aerogenes</i>	4	–	1	–	5
<i>Veillonella sp</i>	–	–	2	–	2
<i>Proteus mirabilis</i>	2	–	–	–	2
<i>Serratia marcescens</i>	2	–	–	–	2
other					
<i>Gardnerella vaginalis</i>	–	1	–	–	1

Number represent number of patients

Table 2. Clinical characteristics of patients with deceased donor liver transplantation.

Characteristics	Donor with positive bacterial cultures		<i>p</i> value
	Group I: Yes, <i>n</i> =98	Group II: No, <i>n</i> =187	
Age, median (range)	52 (33 – 65)	48 (1 – 67)	0.002
Sex (Male:Female)	77:21	132:55	0.160
Hepatitis status			0.403
Hepatitis B positive	51 (52.0%)	110 (58.8%)	
Hepatitis C positive	21 (21.4%)	27 (14.5%)	
Hepatitis B, C positive	3 (3.1%)	9 (4.8%)	
None	23 (23.5%)	41 (21.9%)	
Comorbidity			0.0414
Diabetic Mellitus	13 (13.3%)	14 (7.5%)	
Hypertension	12 (12.2%)	12 (6.4%)	
Chronic renal disease	5 (5.1%)	5 (2.7%)	
Heart disease	3 (3.1%)	0	
Others	3 (3.1%)	6 (3.2%)	
No	72 (73.5%)	157 (84.0%)	
Indication of LT			0.147
Alcoholic Liver cirrhosis	16 (16.3%)	10 (5.4%)	
Virus-related liver cirrhosis	40 (40.8%)	98 (52.4%)	
Hepatocellular carcinoma	32 (32.7%)	46 (24.6%)	
Others	10 (10.2%)	33 (17.6%)	
MELD score, median (range)	21 (7 – 40)	23 (7 – 40)	0.673
Type of grafts			0.0002
Whole liver graft	53 (54.1%)	142 (75.9%)	
Partial liver graft*	45 (45.9%)	45 (24.1%)	
Blood culture after LT (30days)			0.173
Positive bacterial growth	11 (11.2%)	12 (6.4%)	
Negative bacterial growth	87 (88.8%)	175 (93.6%)	
Patient outcomes			0.849
Hospital Mortality (30days)	11 (11.2%)	23 (12.3%)	
Graft dysfunction	0	4 (2.1%)	
Postoperative hemorrhage	2 (2.0%)	5 (2.7%)	
Severe bacterial infections	4 (4.1%)	8 (4.3%)	
Acute rejections	3 (3.1%)	4 (2.1%)	
Others	2 (2.0%)	2 (1.1%)	
Death	30 (30.6%)	62 (33.2%)	

1
2
3
4 Alive

57 (58.2%)

102 (54.5%)

5 LT, liver transplantation; MELD, Model for End-stage Liver Disease. *partial liver grafts
6 included split liver and reduced size liver grafts.
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

1
2
3
4 **Figure legend**
5
6
7

8 **Figure 1.** Flow diagram of organ donors and liver transplantations assessed in this
9
10
11 study.
12
13
14
15
16
17

18 **Figure 2.** The rate of positive bacterial cultures in donors.
19
20
21
22

23
24 **Figure 3. Comparison of cumulative overall survival for the patients show no**
25 **significant difference between the two groups.** Kaplan–Meier overall survival
26 curves of patients. ($p = 0.9746$) Group I (\cdots), Group II ($—$).
27
28
29

30
31 **Figure 4. Comparison of cumulative overall survival for the patients show no**
32 **significant difference between the two groups.** Kaplan–Meier overall survival
33 curves of patients after propensity score matching. ($p = 0.3443$) Group I (\cdots), Group
34 II ($—$).
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only




Figure 1

45x25mm (300 x 300 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60






Figure 2
44x24mm (300 x 300 DPI)



No. at risk		1	2	3	4	5	6	7	8	9	10
Group I	98	72	60	58	51	42	37	32	24	23	20
Group II	187	128	111	98	88	84	80	77	73	72	64

Figure 3A

90x78mm (300 x 300 DPI)



No. at risk		1	2	3	4	5	6	7	8	9	10
Group I	98	72	60	58	49	42	37	32	24	23	20
Group II	98	63	54	45	40	38	36	35	31	30	23

Figure 3B

90x80mm (300 x 300 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Supplemental table 1. Multivariate analyses of clinical features affecting overall survival after liver transplantation.

Factors	Multivariate analysis		
	Hazard Ratio	95% Confidence Interval	<i>p</i> value
Age (years)			
≤55 <i>versus</i> >55	0.99	0.63 – 1.56	0.974
Gender			
Male <i>versus</i> Female	1.17	0.74 – 1.85	0.512
Hepatitis virus			
Hepatitis B positive	0.76	0.45 – 1.29	0.307
Hepatitis C positive	1.27	0.70 – 2.30	0.427
Hepatitis B, C positive	0.48	0.14 – 1.63	0.240
Comorbidity			
Yes <i>versus</i> No	1.29	0.71 – 2.35	0.406
Graft type			
Whole liver <i>versus</i> partial liver	1.56	1.01 – 2.40	0.043
Bacterial cultures of donor			
Positive <i>versus</i> Negative	0.80	0.52 – 1.23	0.310
MELD score			
> 20 <i>versus</i> ≤ 20	1.01	0.99 – 1.04	0.132
Blood cultures after liver transplantation (30 days)			
Positive <i>versus</i> Negative	1.52	0.85 – 2.74	0.160

MELD: model for end-stage liver disease

Reporting checklist for cohort study.

Based on the STROBE cohort guidelines.

Instructions to authors

Complete this checklist by entering the page numbers from your manuscript where readers will find each of the items listed below.

Your article may not currently address all the items on the checklist. Please modify your text to include the missing information. If you are certain that an item does not apply, please write "n/a" and provide a short explanation.

Upload your completed checklist as an extra file when you submit to a journal.

In your methods section, say that you used the STROBE cohort reporting guidelines, and cite them as:

von Elm E, Altman DG, Egger M, Pocock SJ, Gotsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: guidelines for reporting observational studies.

		Reporting Item	Page Number
Title	#1a	Indicate the study's design with a commonly used term in the title or the abstract	1
Abstract	#1b	Provide in the abstract an informative and balanced summary of what was done and what was found	2,3
Background / rationale	#2	Explain the scientific background and rationale for the investigation being reported	5
Objectives	#3	State specific objectives, including any prespecified hypotheses	5,6
Study design	#4	Present key elements of study design early in the paper	5,6
Setting	#5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	6,7
Eligibility criteria	#6a	Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up.	6,7

1		#6b	For matched studies, give matching criteria and number of	8,9
2			exposed and unexposed	
3				
4	Variables	#7	Clearly define all outcomes, exposures, predictors, potential	8,9
5			confounders, and effect modifiers. Give diagnostic criteria, if	
6			applicable	
7				
8				
9				
10	Data sources /	#8	For each variable of interest give sources of data and details of	8,9
11	measurement		methods of assessment (measurement). Describe	
12			comparability of assessment methods if there is more than one	
13			group. Give information separately for for exposed and	
14			unexposed groups if applicable.	
15				
16				
17				
18	Bias	#9	Describe any efforts to address potential sources of bias	7
19				
20	Study size	#10	Explain how the study size was arrived at	6
21				
22				
23	Quantitative	#11	Explain how quantitative variables were handled in the	8,9
24	variables		analyses. If applicable, describe which groupings were chosen,	
25			and why	
26				
27				
28	Statistical	#12a	Describe all statistical methods, including those used to control	8,9
29	methods		for confounding	
30				
31				
32		#12b	Describe any methods used to examine subgroups and	8,9
33			interactions	
34				
35				
36		#12c	Explain how missing data were addressed	See note
37				1
38				
39				
40		#12d	If applicable, explain how loss to follow-up was addressed	See note
41				2
42				
43				
44		#12e	Describe any sensitivity analyses	See note
45				3
46				
47	Participants	#13a	Report numbers of individuals at each stage of study—eg	9
48			numbers potentially eligible, examined for eligibility, confirmed	
49			eligible, included in the study, completing follow-up, and	
50			analysed. Give information separately for for exposed and	
51			unexposed groups if applicable.	
52				
53				
54				
55				
56		#13b	Give reasons for non-participation at each stage	n/a
57				
58		#13c	Consider use of a flow diagram	See note
59				
60				

1				
2				
3	Descriptive data	#14a	Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders. Give information separately for exposed and unexposed groups if applicable.	9-11
4				
5				
6				
7				
8				
9		#14b	Indicate number of participants with missing data for each variable of interest	See note 5
10				
11		#14c	Summarise follow-up time (eg, average and total amount)	11
12				
13	Outcome data	#15	Report numbers of outcome events or summary measures over time. Give information separately for exposed and unexposed groups if applicable.	11
14				
15				
16				
17				
18				
19				
20	Main results	#16a	Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	See note 6
21				
22				
23				
24				
25				
26				
27		#16b	Report category boundaries when continuous variables were categorized	n/a
28				
29				
30				
31		#16c	If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	n/a
32				
33				
34				
35	Other analyses	#17	Report other analyses done—e.g., analyses of subgroups and interactions, and sensitivity analyses	n/a
36				
37				
38				
39	Key results	#18	Summarise key results with reference to study objectives	12
40				
41	Limitations	#19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias.	15
42				
43				
44				
45				
46	Interpretation	#20	Give a cautious overall interpretation considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence.	15
47				
48				
49				
50				
51	Generalisability	#21	Discuss the generalisability (external validity) of the study results	15
52				
53				
54				
55	Funding	#22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which	16
56				
57				
58				
59				
60				

the present article is based

Author notes

1. n/a, no missing data
2. n/a, no loss follow-up patient
3. n/a, not applicable
4. 6, figure 1
5. n/a, no missing data
6. n/a, not applicable

The STROBE checklist is distributed under the terms of the Creative Commons Attribution License CC-BY. This checklist was completed on 30. April 2018 using <http://www.goodreports.org/>, a tool made by the [EQUATOR Network](#) in collaboration with [Penelope.ai](#)